UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark one)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~May~~November 3130, 2018

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission File Number: 0-54236

UBI Blockchain Internet Ltd.

(Exact name of registrant as specified in its charter)

Delaware		27-3349143
(State or Other Jurisdiction of		(I.R.S. Employer
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)
Incorporation or Organization)		Identification No.)

Unit 03, Level 9, Core F, Smart Space,

Block 3, 100 Cyberport Rd.,

Hong Kong, People’s Republic of China

(Address of principal executive offices)

(Zip Code)

(852) 36186110

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ X] Smaller reporting company [X] Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]

~~APPLICABLE~~Indicate ~~ONLY~~the TOnumber ~~REGISTRANTS~~of ~~INVOLVED~~shares INoutstanding ~~BANKRUPTCY~~of each of the issuer’s classes of common stock, as of the latest practicable date. ~~PROCEEDINGS~~As ~~DURING~~of ~~THE~~January ~~PRECEDING~~14, ~~FIVE~~2019, ~~YEARS:~~there were 30,799,046 Class A shares of common stock, par value $0.001; 6,000,000 Class B shares of common stock, par value $0.001, and 73,550,000 Class C shares of common stock, par value $0.001 of the registrant issued and outstanding.

~~Indicate~~UBI byBlockchain ~~check~~Internet ~~mark~~Ltd. ~~whether~~Quarterly ~~the~~Report ~~registrant~~on ~~has~~Form filed all documents and reports required to be filed by Section S 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes [ ] No [X]10-Q

~~APPLICABLE~~For ~~ONLY~~the TOQuarterly ~~CORPORATE~~Period ~~ISSUERS~~Ended November 30, 2018

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of July 15, 2018, there were 30,799,046 Class A shares of common stock, par value $0.001; 6,000,000 Class B shares of common stock, par value $0.001, and 73,400,000 Class C shares of common stock, par value $0.001 of the registrant issued and outstanding.

Table of Contents

~~UBI Blockchain~~Page ~~Internet~~PART ~~Ltd~~I - FINANCIAL INFORMATION 1 Item I. Financial Statements 1 Balance Sheets as of November 30, 2018 (Unaudited) and August 31, 2018 1 Statements of Operations for the Three Months Ended November 30, 2018 (Unaudited) 2 Statements of Cash Flows for the Three Months Ended November 30, 2018 and November 30, 2017 (Unaudited) 3 Notes to Financial Statements (Unaudited) 4 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3. Quantitative and Qualitative Disclosures about Market Risk 27 Item 4. Controls and Procedures 27 PART II. OTHER INFORMATION 28 Item 1 — Legal Proceedings 28 Item 1A — Risk Factors 28 Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3 — Defaults Upon Senior Securities 28 Item 4 — Mine Safety Disclosures 28 Item 5 — Other Information 28 Item 6 — Exhibits 28 SIGNATURES 29

~~Index to Form 10-Q~~i

For the Quarterly Period Ended May 31, 2018

	Page
PART I - FINANCIAL INFORMATION	3
Item I. Financial Statements	3
Balance Sheets as of May 31, 2018 (Unaudited) and August 31, 2017	3
Statements of Operations for the Three and Nine Months Ended May 31, 2018 (Unaudited)	4
Statements of Cash Flows for the Nine Months Ended May 31, 2018 and May 31, 2017 (Unaudited)	5
Notes to Financial Statements (Unaudited)	6
Item 2. - Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Results of Operations	31
Item 3. Quantitative and Qualitative Disclosures about Market Risk	33
Item 4T. Controls and Procedures	34
PART II. OTHER INFORMATION	37
Item 1 — Legal Proceedings	37
Item 1A - Risk Factors	37
Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 3 — Defaults Upon Senior Securities	37
Item 4 — Submission of Matters to a Vote of Security Holders	37
Item 5 — Other Information	37
Item 6 – Exhibits	38
SIGNATURES	39

PART I - FINANCIAL INFORMATION

Item 1. ~~Financials~~Financial Statements

UBI Blockchain Internet, Ltd.

(Formerly JA Energy)

~~Consolidated~~Condensed Unaudited Consolidated Balance Sheets

	May 31, 2018			August 31, 2017
	November 30, 2018			August 31, 2018
	(Unaudited)
Assets
Current Assets
Cash	$	55189,~~245~~323		$	1523,~~406~~434
Inventory		2523,~~025~~083			-23,448
Current portion of prepaid stock-based salaries and consulting fees		~~678~~308,333			1493,~~300,000~~333
Deposit and prepaid expenses		325,~~691~~651			-18,093
Total Current Assets		~~762~~546,~~294~~390			1558,~~315,406~~308
Office equipment, net of accumulated depreciation		207,~~729~~170			179,~~950~~359
Other Assets
Non-current portion of prepaid stock-based salaries and consulting fees		-			~~493,333~~-
Intangible assets, net of accumulated amortization		~~110~~117,~~795~~553			92127,~~035~~037
Total Other Assets		~~110~~117,~~795~~553			~~585~~127,~~368~~037
Total Assets	$	~~893~~671,~~818~~113		$	1694,~~918,724~~704
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable and accrued liabilities	$	~~113~~160,~~883~~032		$	71151,~~425~~405
Due to related party		12,~~618~~365,~~542~~721			~~514~~1,~~081~~923,599
Total current liabilities		12,~~732~~525,~~425~~753			~~585~~2,~~506~~075,004
Total liabilities		12,~~732~~525,~~425~~753			~~585~~2,~~506~~075,004
Stockholders’ Equity (Deficit):
Preferred Stock: $0.001 par value, 5,000,000 shares authorized, 0 and 0 shares issued and outstanding as of February 28, 2018 and August 31, 2017, respectively		-			-
Preferred Stock: $0.001 par value, 5,000,000 shares authorized, 0 and 0 shares issued and outstanding as of November 30, 2018 and August 31, 2018, respectively		-			-
Class A common stock, $0.001 par value, 1,000,000,000 shares authorized, 30,799,046 and 30,717,046 shares issued and outstanding as of February 28, 2018 and August 31, 2017, respectively		30,799			30,717
Class A common stock, $0.001 par value, 1,000,000,000 shares authorized, 30,799,046 and 30,799,046 shares issued and outstanding as of November 30, 2018 and August 31, 2018, respectively		30,799			30,799
Class B common stock, $0.001 par value, 500,000,000 shares authorized, 6,000,000 and 6,000,000 shares issued and outstanding as of February 28, 2018 and August 31, 2017, respectively		6,000			6,000
Class B common stock, $0.001 par value, 500,000,000 shares authorized, 6,000,000 and 6,000,000 shares issued and outstanding as of November 30, 2018 and August 31, 2018, respectively		6,000			6,000
Class C common stock, $0.001 par value, 500,000,000 shares authorized, 73,400,000 and 73,400,000 shares issued and outstanding as of February 28, 2018 and August 31, 2017, respectively		73,400			73,400
Class C common stock, $0.001 par value, 500,000,000 shares authorized, 73,550,000 and 73,550,000 shares issued and outstanding as of November 30, 2018 and August 31, 2018, respectively		73,550			73,550
Additional paid in capital		7,~~811~~841,~~721~~571			7,~~475~~841,~~931~~571
Stock subscription payable		90,521			90,521
Accumulated other comprehensive income		(127,~~009~~169	)		7525,051
Accumulated deficit		(89,~~850~~924,~~039~~250	)		(69,~~343~~447,~~426~~792	)
Total stockholders’ equity (deficit)		(~~838~~1,~~607~~854,640	)		(1,~~333~~380,~~218~~300	)
Total liabilities and Stockholders’ Equity (Deficit)	$	~~893~~671,~~818~~113		$	1694,~~918,724~~704

The accompanying notes are an integral part of these consolidated financial statements.

UBI Blockchain Internet, Ltd.

(Formerly JA Energy)

~~Consolidated~~Condensed Unaudited Consolidated Statements of Operations

	For the three months ended May 31, 2018			For the three months ended May 31, 2017			For the nine months ended May 31, 2018			For the nine months ended May 31, 2017
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Revenue	$	-		$	-		$	-		$	-
Operating Expenses:
Employee compensation (including stock-based compensation of $0, $72,500, $96,668 and $120,833 respectively)		180,980			190,701			641,036			370,270
Consulting fees (including stock-based compensation of $185,000, $409,167, $1,018,333 and $640,834 respectively		185,000			409,167			1,023,383			665,834
Depreciation and amortization		6,697			318			11,021			318
Professional fees (including stock-based compensation of $0, $0, $335,872 and $0, respectively)		61,280			53,652			454,152			93,168
Occupancy		25,359			-			65,049			-
Research and development		86,717			-			158,496			-
Other		28,898			14,831			100,392			41,070
Total Operating Expenses		574,931			668,669			2,453,529			1,170,660
Loss from Operations		(574,931	)		(668,669	)		(2,453,529	)		(1,170,660	)
Other Income (Expenses)
Interest expense - related party		(24,024	)		-			(52,869	)		-
Gain (loss) on foreign currency exchange		(157	)		-			(215	)		-
Gain on settlement of accounts payable and accrued liabilities		-			-			-			47,003
Gain on settlement of bank overdraft		-			-			-			572
Total Other Income (Expenses) - net		(24,181	)		-			(53,084	)		47,575
Net Loss		(599,112	)		(668,669	)		(2,506,613	)		(1,123,085	)
Other comprehensive income (loss):
Foreign exchange translation adjustment		6,415			-			(1,084	)		-
Comprehensive Loss	$	(592,697	)	$	(668,669	)	$	(2,507,697	)	$	(1,123,085	)
Net Loss per share of Class A, Class B, and Class C Common Stock
Basic and Diluted	$	(0.01	)	$	(0.01	)	$	(0.02	)	$	(0.03	)
Weighted Average Number of Class A, Class B, and Class C Common Shares
Basic and Diluted		110,199,046			75,772,480			110,189,700			41,424,290

For the Three Months Ended November 30,

	2018			2017

Revenue From Development Agreements	$	112,445		$	-

Operating Expenses:
Employee compensation (including stock-based compensation of $0 and $72,500, respectively)		173,552			263,963
Consulting fees (including stock-based compensation of $185,000 and $532,500, respectively		185,000			532,500
Professional fees (including stock-based compensation of $0 and $335,872, respectively)		68,620			343,872
Occupancy		32,653			16,621
Depreciation and amortization		9,644			2,119
Other		84,454			64,449
Total Operating Expenses		553,923			1,223,524

Loss from Operations		(441,478	)		(1,223,524	)

Other Income (Expenses)
Interest expense - related party		(34,781	)		(10,826	)
Interest income		14			-
Gain (loss) on foreign currency exchange		(213	)		10
Total Other Income (Expenses) - net		(34,980	)		(10,816	)

Net Loss		(476,458	)		(1,234,340	)

Other comprehensive income (loss):
Foreign exchange translation adjustment		2,118			(785	)
Comprehensive Loss	$	(474,340	)	$	(1,235,125	)

Net Loss per share of Class A, Class B, and Class C Common Stock
Basic and Diluted	$	(0.00	)	$	(0.01	)

Weighted Average Number of Class A, Class B, and Class C Common Shares
Basic and Diluted		110,349,046			110,214,181

The accompanying notes are an integral part of these consolidated financial statements.

UBI Blockchain Internet, Ltd.

(Formerly JA Energy)

~~Consolidated~~Condensed Unaudited Consolidated Statements of Cash Flows

	For the nine months ended May 31, 2018			For the nine months ended May 31, 2017
	(Unaudited)			(Unaudited)
Cash Flows from Operating Activities
Net Loss	$	(2,506,613	)	$	(1,123,085	)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization expenses		11,021			318
Stock-based compensation - employees		96,668			120,833
Stock-based compensation - consulting fees		1,018,333			640,834
Stock-based compensation - professional fees		335,872			-
Gain on settlement of bank overdraft		-			(572	)
Gain on settlement of accounts payable and accrued liabilities					(47,003	)
Changes in operating assets and liabilities:
Increase in inventory		(24,806	)
Increase in deposit and prepaid expenses		(3,659	)		(3,000	)
Increase (decrease) in accounts payable and accrued liabilities		41,966			(1,285	)
Increase (decrease) in bank overdraft		-			(630	)
Increase in interest payable to related party		52,796			-
Net cash used by operating activities		(978,422	)		(413,590	)
Cash Flows from investing activities
Website and software development costs		(20,114	)		-
Purchases of office equipment		(9,302	)		(6,363	)
Net cash used by operating activities		(29,416	)		(6,363	)
Cash Flows from financing activities
Repayments of advances payable to former related party		-			(26,981	)
Advance from related party		1,047,943			333,169
Repayment of note payable to former related party		-			(50,000	)
Buyback of preferred stock		-			(33,735	)
Proceeds from sale of common stock - net		-			180,000
Contributed capital		-			17,500
Net cash provided by financing activities		1,047,943			419,953
Effect of exchange rate on cash		(265	)		-
Net Increase (Decrease) in Cash		39,840			-
Cash and cash equivalents at beginning of period		15,405			-
Cash and cash equivalents at end of period	$	55,245		$	-
Supplemental Cash Flow Information:
Income taxes paid	$	-		$	-
Interest paid	$	-		$	-
Non-cash Investing and Financing Activities:
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of 8,400,000 shares of Class C common stock to 7 employees and 38 consultants on April 3, 2017 charged to prepaid stock based salaries and consulting fees	$	-		$	1,680,000
Issuance of 500,000 shares of Class A common stock to consultant on May 1, 2017 charged to prepaid stock based salaries and consulting fees	$	-		$	1,480,000

For the Three Months Ended November 30,

	2018			2017

Cash Flows from Operating Activities
Net Loss	$	(476,458	)	$	(1,234,340	)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization expense		9,644			2,119
Stock-based compensation - employees		-			72,500
Stock-based compensation - consulting fees		185,000			532,500
Stock-based compensation professional fees		-			335,872
Changes in operating assets and liabilities:
Increase in deposit and prepaid expenses		(7,884	)		(5,000	)
Increase in accounts payable and accrued liabilities		8,488			53,632
Increase in interest payable to related party		34,781			10,824
Net cash used by operating activities		(246,429	)		(231,893	)

Cash Flows from investing activities		-			-

Cash Flows from financing activities
Loans from related party		413,054			279,540
Net cash provided by financing activities		413,054			279,540

Effect of exchange rate on cash		(736	)		(47	)
Net Increase in Cash		165,889			47,600
Cash and cash equivalents at beginning of period		23,434			15,406
Cash and cash equivalents at end of period	$	189,323		$	63,006

Supplemental Cash Flow Information:
Income taxes paid	$	-		$	-
Interest paid	$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements.

UBI BLOCKCHAIN INTERNET LTD.

(FORMERLY JA ENERGY)

NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE ~~NINE~~THREE MONTHS ENDED ~~MAY~~NOVEMBER 3130, 2018 AND 2017

(UNAUDITED)

NOTE 1 – ABOUT THE COMPANY

Organization and Capitalization of the Company

The Company was organized August 26, 2010 (Date of Inception) under the laws of the State of Nevada, as JA Energy. The Company was incorporated as a subsidiary of Reshoot Production Company, a Nevada corporation. Reshoot Production Company was incorporated October 31, 2007. In November 2014, Reshoot dividended its shares of JA Energy to the then stockholders of Reshoot. On November 21, 2016, the Company reincorporated in Delaware under the name UBI Blockchain Internet Ltd.

On September 15, 2016, the Company, with the approval of the Board of Directors agreed to issue 30,000,000 shares of unregistered restricted Class A Common Stock, 6,000,000 shares of unregistered restricted Class B Voting Common Stock, which carries a voting weight equal to ten (10) Common Shares, and 40,000,000 shares of unregistered restricted Class C Common Stock to UBI Blockchain Internet, LTD (“UBI Hong Kong”), a Hong Kong company, or assigns in exchange for $200,000. On September 26, 2016, pursuant to NRS 78.1955, the Board of Directors approved the filing of a Certificate of Designation with the Nevada Secretary of State to designate Class A, B and C common shares, par value $0.001. Concurrently with the filing of this Certificate of Designation, all Common Stock issued and outstanding became Class A Common Stock. Class B Common Stock carries a voting weight equal to ten (10) Common Shares. The Class B shares can be converted into fully paid and non-assessable Common Shares, on a one-to-one basis, at the option of the holder at any time upon written notice to the Company and its authorized transfer agent. Class C Common Stock has no voting ~~rights. Upon the conversion~~ or other exchange of all outstanding shares of Class B Common Stock into or for shares of Class A Common Stock, all shares of Class C Common Stock shall be automatically, without further action by any holder thereof, converted into an identical number of fully paid and non-assessable shares of Class A Common Stock on the date fixed therefore by the Board of Directors that is no less than sixty-one days and no more than one hundred and eighty days following such conversion or ~~exchange~~rights.

On October 7, 2016, the 30,000,000 Class A shares and 6,000,000 Class B shares were issued.

On November 21, 2016, the Company reincorporated in Delaware under the name UBI Blockchain Internet Ltd. and increased the number of authorized shares from 75,000,000 to 200,000,000 shares consisting of 130,000,000 authorized shares of Class A Common Stock, 6,000,000 authorized shares of Class B Common Stock and 64,000,000 authorized shares of Class C Common Stock. On March 1, 2017, the 40,000,000 shares of Class C common stock were issued. All of the preceding shares were issued in reliance on the exemption under Section 4(2) of the Securities Act of 1933, as amended (the “Act”) and were issued under Regulation S to one (1) foreign entity who attested it is an accredited investor who is not a citizen or a resident of the USA.

On January 3, 2017, the Company appointed four new directors, accepted the resignations of its two former directors and appointed Tony Liu (who controls UBI Hong Kong) as Chief Executive Officer of the Company.

Commencing in the three months ended February 28, 2017, the Company started research activities in Hong Kong relating to “blockchain” technology planned to be provided for future customers.

On March 1, 2017, the Company issued 40,000,000 shares of Class C common stock to our chief executive officer Tony Liu pursuant to the September 15, 2016 agreement (see above).

On April 3, 2017, the Company issued a total of 8.400,000 shares of Class C common stock to a total of 45 contractor employees and nonemployees (see Note 7).

On May 1, 2017, the Company issued 500,000 restricted shares of Class A common stock to an independent consultant for consulting services to be performed for the Company (see Note 7).

On May 24, 2017, the Company increased the number of authorized common shares from 200,000,000 shares to 2,000,000,000 shares (1,000,000,000 shares of Class A common stock, 500,000,000 shares of Class B common stock, and 500,000,000 shares of Class C common stock).

On August 29, 2017, upon the approval of the acquisition by the related PRC authorities, the Company issued a total of 25,000,000 shares of Class C common stock to shareholders of Shenzhen Nova E-commerce, Ltd. (“Nova”) in exchange for control of the business of Nova (see Notes 4 and 7). On April 7, 2018, Nova changed its name to UBI Shenzhen Cross Border E- Commerce Co., Ltd. (“UBI Shenzhen”).

Current Company Operations

UBI Blockchain Internet Ltd. (“UBI Delaware”) was reincorporated in Delaware on November 21, 2016 for the purpose of entering into the blockchain technology business. UBI Blockchain Internet, Ltd (“UBI Hong Kong”) was organized in the Hong Kong Special Administrative Region (the “HKSAR”) in September 2016 to facilitate local financing participations,. UBI Delaware opened a bank account at Abacus Federal Savings Bank in New York City. This bank account is funded by Tony Liu and is used to pay Company invoices from the U.S. UBI Hong Kong has a bank account at China Citic Bank International in Hong Kong, which is also funded by Tony Liu; this account makes disbursements relating to UBI Delaware operations in Hong Kong (such as payroll, rent, and other office expenses). UBI Hong Kong is owned and controlled by Tony Liu, CEO of UBI Delaware. UBI Hong Kong owns 30,000,000 (97%) of the 30,799,046 issued and outstanding shares of UBI Delaware Class A common stock at ~~May~~November 3130, 2018. UBI Hong Kong ~~has~~ has no other assets and no business operations of its own.

In December 2016, UBI Delaware engaged the services of 8 full time employees to principally work in its blockchain technology business. In January 2018, UBI Hong Kong executed an agreement with the HKSAR and The Hong Kong Polytechnic University to complete a project related to blockchain technology (see Note 12). ToThrough ~~date~~August 31, 2018, UBI Delaware, ~~has~~UBI ~~not~~Hong ~~received~~Kong, and UBI Shenzhen did not receive or ~~earned~~earn any revenues in its blockchain technology business.

NOTE 2 - GOING CONCERN

The accompanying condensed unaudited financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. At ~~May~~November 3130, 2018, the Company had cash of $55189,~~245~~323 and current liabilities of $12,~~732~~525,~~425~~753. For the ~~nine~~three months ended ~~May~~November 3130, 2018, the Company incurred a net loss of $2476,~~506,613~~458. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The accompanying condensed unaudited financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from the outcome of this uncertainty.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

The relevant accounting policies are listed below.

Interim Financial Statements

The consolidated balance sheet ~~for~~of the Company at the end of the preceding fiscal year has been derived from the audited balance sheet and notes thereto contained in the Company’s annual report on Form 10-K for the fiscal year ended August 31, ~~2017~~2018 and is presented herein for comparative purposes. All other financial statements are unaudited. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the financial position, results of operations and cash flows for all period presented, have been made. The results of operations for the interim periods presented are not necessarily indicative of the operating results for the respective full years.

Certain footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) have been omitted in accordance with the published rules and regulations of the Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended August 31, 2017 filed with the SEC on December 7, 2017, for which notes to the financial statements as of August 31, 2017 were enhanced to include disclosures concerning “Current Company Operations” (as discussed in Note 1 above) and “Right of Rescission Contingency” (as discussed in Note 12 in below), pursuant to Post Effective Amendment Nos. 2, 4, and 5 ~~to Form S-1 respectively filed on April 4, 2018, May 11, 2018, and June 27, 2018.~~

Basis of Accounting

The ~~basis~~accompanying iscondensed ~~United~~unaudited ~~States~~consolidated ~~generally~~financial ~~accepted~~statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).

Principles of Consolidation

The accompanying condensed unaudited consolidated financial statements include the accounts of UBI Blockchain Internet Ltd. and its wholly owned subsidiary UBI Shenzhen Cross Border E-Commerce Co., Ltd, (“UBI Shenzhen”), formerly Shenzhen Nova E-commerce, Ltd. (“Nova”) from the date of acquisition of Nova on August 29, 2017 (see Note 4). All intercompany ~~accounts~~balances and transactions have been eliminated in consolidation.

Earnings per Share

The basic earnings (loss) per share of Class A, Class B and Class C common stock is calculated by dividing the Company’s net income (loss) available to Class A, Class B and Class C common shareholders by the weighted average number of Class A, Class B and Class C common shares issued and outstanding during the period. The diluted earnings (loss) per share of Class A, Class B and Class C common stock is calculated by dividing the Company’s net income (loss) available to Class A, Class B and Class C common shareholders by the diluted weighted average number of Class A, Class B and Class C shares outstanding during the period. The diluted weighted average number of Class A, Class B and Class C shares outstanding is the basic weighted average number of Class A, Class B, and Class C shares adjusted as of the first day of the period for any potentially dilutive debt or equity (none for the periods presented).

Cash and Cash Equivalents

The Company considers all short-term investments with a maturity of three months or less at the date of purchase to be cash and cash equivalents.

8Of the $189,323 cash at November 30, 2018, $182,969 was held in foreign bank account not insured by FDIC.

Use of Estimates

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.

Inventory

Inventory, consisting of finished goods purchased from third parties, are stated at the lower of cost (first-in, first-out method) or market.

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight-line basis over the estimated useful lives of the respective assets. Expenditures for repairs and maintenance are expensed as incurred.

Intangible Assets

Intangible assets, including website development costs, ~~and~~ software acquired to be marketed, and office software, are carried at cost less accumulated amortization. Intangible assets are amortized using the straight-line method over the estimated economic lives of the respective assets (5 years for website development costs and 5 years for the software acquired to be marketed and the office software).

Software development costs include payments made to independent software developers under development agreements, as well as direct costs incurred for internally developed products. Software development costs are capitalized once technological feasibility of a product is established and such costs are determined to be recoverable. Technological feasibility of a product requires both technical design documentation and game design documentation, or the completed and tested product design and a working model. Significant management judgments and estimates are utilized in the assessment of when technological feasibility is established and the evaluation is performed on a product-by-product basis. For products where proven technology exists, this may occur early in the development cycle. Software development costs related to hosted service revenue arrangements are capitalized after the preliminary project phase is complete and it is probable that the project will be completed and the software will be used to perform the function intended. Prior to a product’s release, if and when we believe capitalized costs are not recoverable, we expense the amounts. Capitalized costs for products that are canceled or are expected to be abandoned are expensed in the period of cancellation. Amounts related to software development which are not capitalized are charged immediately to “Research and development”.

Foreign Currency Translation

The reporting currency and functional currency of the Company is the United States Dollar.

The functional currency of UBI Shenzhen is the Chinese Renminbi (“RMB”). Assets and liabilities of UBI Shenzhen are ~~translated~~ translated into United States dollars at period-end exchange rates ($1.00 = 6.~~4066~~94577 RMB at ~~May~~November 3130, 2018 and $1.00 = 6.~~5876~~83750 RMB at August 31, ~~2017~~ 2018). UBI Shenzhen revenues and expenses are translated into United States dollars at weighted average exchange rates ($1.00 = 6.~~333~~90730 RMB for the three months ended ~~May~~November 3130, 2018 and $1.00 = 6.~~528~~60580 RMB for the ~~nine~~three months ended ~~May~~November 3130, ~~2018~~2017). Resulting translation adjustments are recorded as a component of accumulated other comprehensive income (loss) within stockholders’ equity.

~~Transactions~~The ~~denominated~~functional incurrency ~~currencies~~of ~~other~~UBI ~~than~~HK ~~the~~is ~~functional currency (principally~~ the Hong Kong Dollar (“HK$”). Assets and liabilities of UBI HK are translated into United States dollars at ~~the~~period-end exchange rates ~~prevailing~~($1.00 = 7.8221 HK$ at ~~the~~November ~~dates~~30, of2018 ~~the~~and ~~transactions~~$1.00 ~~Exchange~~= ~~gains~~7.8494 ~~and~~HK$ ~~losses~~at August 31, 2018). ~~which~~UBI ~~were~~HK ~~not~~revenues ~~significant~~and expenses are translated into United States dollars at weighted average exchange rates ($1.00 = 7.8351 HK$ for the three ~~and nine~~ months ended ~~May~~November 3130, 2018 and $1.00 = 7.8080 HK$ for the three months ended November 30, 2017). ~~were~~Resulting translation ~~reflected~~adjustments inare recorded as a component of accumulated other comprehensive income (loss) within stockholders’ equity.

Transactions denominated in currencies other than the functional currency are translated at the exchange rates prevailing at the dates of the transactions. Exchange gains and losses, which were not significant for the three months ended November 30, 2018 and 2017 were reflected in income.

Income Taxes

The provision for income taxes is the total of the current taxes payable and the net of the change in the deferred income taxes. Provision is made for the deferred income taxes where differences exist between the period in which transactions affect current taxable income and the period in which they enter into the determination of net income in the financial statements.

Revenue recognition

The Company recognizes revenue from services and product sales once all the following criteria for revenue recognition have been met: pervasive evidence that an agreement exists; the services or products have been delivered; the fee is fixed and determinable and not subject to refund or adjustment; and collection of the amount due is reasonably assured. ~~For the periods presented, the Company had no revenues.~~

Stock-Based Compensation

The Company accounts for employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, “Compensation - Stock Compensation,” which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The Company does not have an employee stock option plan.

The Company follows ASC topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock issued to consultants and other non-employees. In accordance with ~~ACS~~ASC Topic 505-50, the stock issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the stock, whichever can be more clearly determined. The fair value of the equity instrument is charged directly to expense over the period during which services are rendered.

Year end

The Company’s fiscal year-end is August 31.

Related Parties

Related parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions.

Recent Accounting Pronouncements

Certain accounting pronouncements have been issued by the FASB and other standard setting organizations which are not yet effective and therefore have not yet been adopted by the Company. The impact on the Company’s financial position and results of operations ~~form~~from adoption of these standards is not expected to be material.

NOTE 4 – ACQUISITION OF UBI SHENZHEN CROSS BORDER E-COMMERCE CO., LTD (FORMERLY NOVA E-COMMERCE, LTD.)

On August 29, 2017, pursuant to an Acquisition Agreement dated May 16, 2017, the Company acquired 100% ownership of UBI Shenzhen Cross Border E-Commerce Co., Ltd. (“UBI Shenzhen”), formerly Shenzhen Nova E-commerce, Ltd. (“Nova”), in exchange for 25,000,000 shares of Company Class C common stock. UBI Shenzhen is a Shenzhen Chinese corporation which was incorporated on May 26, 2016. UBI Shenzhen plans on operating an online store in China selling a wide range of products.

The acquisition has been accounted for as a recapitalization transaction in the accompanying condensed unaudited consolidated financial statements. Accordingly, the financial position and results of operations of UBI Shenzhen prior to the August 29, 2017 date of acquisition have been excluded from the accompanying condensed unaudited consolidated financial statements.

The carrying values of the assets and liabilities of UBI Shenzhen at the August 29, 2017 date of acquisition consisted of:

Cash	$	-
Office equipment, net		13,628
Website development costs		92,035
Total assets		105,663

Accounts payable and accrued liabilities		24,651
Due to related party		135,865
Total liabilities		160,516

Excess of liabilities over assets	$	54,853

109

The following proforma information (unaudited) summarizes the results of operations for the three and nine months ended May 31, 2017 as if UBI Shenzhen was acquired on May 26, 2016 (UBI Shenzhen’s date of inception). The pro forma information is not necessarily indicative of the results that would have been reported had the transaction actually occurred on May 26, 2016, not is it intended to project results of operations for any future period.

	Three Months Ended May 31, 2017			Nine Months Ended May 31, 2017
	(Unaudited)			(Unaudited)
Revenue	$	-		$	-
Operating expenses:
Employee compensation (including stock - based compensation of $72,500 and $120,833, respectively)		211,880			433,807
Consulting fees (including stock - based compensation of $409,167 and $640,834, respectively)		409,167			665,834
Professional fees		53,652			93,168
Marketing		57,762			173,286
Occupancy		18,580			55,741
Other		15,714			43,083
Total operating expenses		766,755			1,464,919
Loss from Operations		(766,755	)		(1,464,919	)
Other Income (expenses):
Gain on settlement of accounts payable and accrued liabilities		-			47,003
Gain on settlement of bank overdraft		-			572
Net Loss	$	(766,755	)	$	(1,417,344	)
Net Loss per share of Class A, Class B, and Class C common stock - basic and diluted	$	(0.01	)	$	(0.02	)
Weighted average number of Class A, Class B, and Class C Common Shares outstanding - basic and diluted		100,635,494			66,287,304

NOTE 5 – PREPAID STOCK BASED SALARIES AND CONSULTING FEES

Prepaid stock-based salaries and consulting fees at ~~May~~November 3130, 2018 and August 31, ~~2017~~2018 consist of:

	Fair value of stock issuance (Note 6)		Prepaid balance at ~~May~~November 3130, 2018			Prepaid balance at August 31, ~~2017~~2018
1,450,000 shares of Class C common stock issued to 7 employees on April 3, 2017 pursuant to service agreements between UBI Delaware and the respective employees with a service term of one year which expired December 31, 2017	$	290,000	$	-		$	96,667
1,450,000 shares of Class C common stock issued to 7 employees on April 3, 2017 pursuant to service agreements between UBI Delaware and the respective employees with a service term of one year expiring December 31, 2017	$	290,000	$	-		$	-
6,950,000 shares of Class C common stock issued to 38 consultants on April 3, 2017 pursuant to service agreements between UBI Delaware and the respective consultants with a service term of one year which expired December 31, 2017		1,390,000		-			463,333
6,950,000 shares of Class C common stock issued to 38 consultants on April 3, 2017 pursuant to service agreements between UBI Delaware and the respective consultants with a service term of one year expiring December 31, 2017		1,390,000		-			-
500,000 shares of Class A common stock issued to a consultant on May 1, 2017 pursuant to Consulting Agreement dated April 28, 2017 between UBI Delaware and the respective consultant with a service term of two years expiring April 30, 2019		1,480,000		~~678~~308,333			1493,~~233,~~333
Total	$	3,160,000		~~678~~308,333			1493,~~793,~~333
Current portion				(~~678~~308,333	)		(1493,~~300,000~~333	)
Non-current portion			$	-		$	~~493,333~~-

At ~~May~~November 3130, 2018, there was $~~678~~308,333 of unrecognized compensation costs related to shares of Class A common stock issued to a ~~consultant~~ consultant pursuant to a Consulting Agreement dated April 28, 2017 with a service term of two years expiring April 30, 2019. These ~~costs~~ costs are expected to be recognized as expense in the ~~three~~year ~~months~~ ended August 31, ~~2018 ($185,000) and in the year ending August 31,~~ 2019 ~~($493,333)~~.

NOTE 6 – INTANGIBLE ASSETS

Intangible assets at ~~May~~November 3130, 2018 and August 31, ~~2017~~2018 consist of:

	May 31, 2018			August 31, 2017
	November 30, 2018			August 31, 2018
Website development costs	$	9492,~~652~~488		$	9293,~~035~~952
Accumulated amortization		(412,~~149~~938	)		-(11,278	)
Website development costs, net		9079,~~503~~550			9282,~~035~~674
Software acquired to be marketed		2036,~~292~~713			-37,294
Accumulated amortization		-(4,624	)		-
Software acquired to be marketed, net		2032,~~292~~089			-37,294
Total intangible assets - net	$	110,795		$	92,035
Office software		8,350			8,483
Accumulated amortization		(2,436	)		(1,414	)
Office software, net		5,914			7,069
Total intangible assets - net	$	117,553		$	127,037

1210

At ~~May~~November 3130, 2018, the expected future amortization expense of the intangible assets was:

	Amount
Years ending	Amount
Three months ending August 31, 2018	$	4,733
November 30, 2019	$	27,510
Year ending August 31, 2019		22,988
November 30, 2020		27,510
Year ending August 31, 2020		22,988
November 30, 2021		27,510
Year ending August 31, 2021		22,988
November 30, 2022		27,510
Year ending August 31, 2022		22,988
November 30, 2023		7,513
Year ending August 31, 2023		14,110
Total	$	117,553
Total	$	110,795

Website Development Costs

In January 2018, UBI Shenzhen changed the domain name for its website from www.oyamall.com to www.hihealth8.com. The change was made to, among other things, correct certain technical problems which we experienced in testing potential transactions involving Chinese currency. UBI Shenzhen’s website became operational on March 12, 2018.

UBI Shenzhen has yet to generate any revenues, ~~and~~from ~~management does not expect UBI Shenzhen will generate any revenues for the next few months, until such time as the Company actively markets~~ its website. In ~~the meantime, in~~ order for UBI Shenzhen to begin its business operations, UBI Shenzhen will be selling third party products. In the future, management plans to develop its own products for sale. ~~UBI Shenzhen became a wholly owned subsidiary of the Company.~~ It was a management decision to acquire UBI Shenzhen for primarily two business reasons: 1) as a separate subsidiary, once UBI Shenzhen is fully operational, management anticipates it should generate revenues and profit for the Company; and 2) this acquisition provides a test model to utilize the blockchain technology the Company is developing to track drug products sold by UBI Shenzhen. As a test model, this will allow the Company to see if the products sold through its website are substituted with counterfeit products before they reach the final consumer. In other words, products sold through a third-party consumer will be tracked using the Company’s blockchain technology to see if there is a break in the supply chain. This will take place once the Company develops its blockchain digital tracking system. The Company will be able to monitor UBI Shenzhen shipments to the final consumer, to determine if there has been any tampering with shipments in the supply chain.

UBI Shenzhen employs two people principally involved in website related creation/maintenance activities. UBI Shenzhen’s expenses are being funded by loans from Tony Liu.

Software Acquired to be Marketed

On November 24, 2017, January 17, 2018 and March 15, 2018, UBI Shenzhen executed agreements with a third-party vendor to produce customized game software called Farmer Game for a total of RMB 285,000 ($4441,~~485~~682 using the ~~May~~August 31, 2018 exchange rate). UBI Shenzhen expects to use the Farmer Game to attract more visitors to its website and to potentially earn revenues from users’ use of game points to purchase products sold on the website. Farmer Game is expected to be introduced to website visitors in ~~August~~the near ~~2018~~future.

~~Through~~In ~~May~~the year ended August 31, 2018, UBI Shenzhen ~~has~~ paid the Farmer Game vendor a total of RMB ~~160~~285,000 ($2441,~~974~~682), of which RMB 30,000 ($4,~~682~~388) ~~has been~~was expensed ~~as “Research~~ and ~~development”~~RMB ~~and RBM 130~~255,000 ($2037,~~992~~294) ~~has~~was ~~been~~ capitalized. ~~On June 25, 2018, UBI Shenzhen paid RMB 105,000 ($16,389) of the remaining contract balance of RMB 125,000 ($19,511) due the vendor.~~

NOTE 7 - STOCKHOLDERS’ EQUITY

Pursuant to the September 15, 2016 change in control agreement (see Note 1), a representative of UBI paid into an attorney trust account $150,000 on September 14, 2016 and $67,500 on October 11, 2016, for a total of $217,500. The $217,500 consisted of $200,000 for the newly issued shares of Class A, Class B Voting, and Class C Common Stock and $17,500 for the payment of specific expenses.

Starting in December 2016, the Company engaged the services of a total of 45 employees and non-employees to perform certain marketing, research and development and investor relations services. The related agreements, which were executed in March 2017, provided for the contractors to work for the Company for terms ranging from September 2016 to January 1, 2017 to December 31, 2017 for compensation including the issuance of a total of 8,400,000 shares of Class C common stock (which occurred April 3, 2017). Of the 8,400,000 shares, 5,000,000 shares were issued to Star Bright International Investment ~~Enterprises~~Enterprise Limited, 100,000 shares were issued to the Company’s chief financial officer and 500,000 shares were issued to an independent Director of the Company.

The $1,680,000 estimated fair value of the 8,400,000 shares of Class C common stock (using a price of $0.20 per share) was recorded as prepaid expenses and was expensed evenly over the year ended December 31, 2017 (see Note 5). For the nine months ended May 31, 2018, we recognized stock-based salaries expense of $96,668 and recognized stock-based consulting fees expense of $463,333 from these agreements.11

On May 1, 2017, the Company issued 500,000 restricted shares of Class A common stock to a consultant pursuant to a Consulting Agreement dated April 28, 2017 with a service term of two years expiring April 30, 2019. The $1,~~480~~680,000 estimated fair value of the ~~500~~8,400,000 shares of Class AC common stock (using a price of $20.9620 per share ~~based on a $3.95 closing trading price on April 28, 2017 less a 25% restricted stock discount~~) was recorded as a prepaid ~~expense~~expenses and iswas ~~being~~ expensed evenly over the 2-year ~~service~~ended ~~period expiring~~December ~~April 30~~31, ~~2019~~2017 (see Note 5). For the ~~nine~~three months ended ~~May 31~~November 30, 2018 and 2017, we recognized stock-based employee compensation of $0 and $72,500, respectively and recognized stock-based consulting fees expense of $~~555~~0 and $347,~~000~~ 500, respectively, from ~~this~~these ~~agreement~~agreements.

On May 1, 2017, the Company issued 500,000 restricted shares of Class A common stock to a consultant pursuant to a Consulting Agreement dated April 28, 2017 with a service term of two years expiring April 30, 2019. The $1,480,000 estimated fair value of the 500,000 shares of Class A common stock (using a price of $2.96 per share based on a $3.95 closing trading price on April 28, 2017 less a 25% restricted stock discount) was recorded as a prepaid expense and is being expensed evenly over the 2-year service period expiring April 30, 2019. For the year ended August 31, 2018, we recognized stock-based consulting fees expense of $740,000 from this agreement. For the three months ended November 30, 2018 and 2017, we recognized stock-based consulting fees expense of $185,000 and $185,000, respectively, from this agreement.

On August 29, 2017, upon the regulatory approval of the transfer of Nova’s Hong Kong business license to the Company, the Company acquired 100% ownership of Nova in exchange for the Company’s issuance of a total of 25,000,000 shares of Class C common stock to the 130 owners of Nova.

On October 2, 2017, the Company issued a total of 82,000 restricted shares of Class A common stock to 4 individuals associated with the Company’s law firm for legal services rendered. The $335,872 estimated fair value of the 82,000 shares of Class A common stock (using a price of $4.10 per share based on a $5.12 closing trading price on October 2, 2017 less a 20% restricted stock discount) was expensed in the three months ended November 30, 2017.

On December 26, 2017, the Company’s Board of Directors approved a 3 for 1 common stock dividend of the Company’s issued and outstanding Class A and Class B common stock. On January 2, 2018, the Company was advised by FINRA to resubmit its request as a forward stock split instead of a stock dividend.

On January 4, 2018, the Company’s Board of Directors approved a 4 for 1 forward stock split for holders of record on January 10, 2018 of the Company’s issued and outstanding shares of Class A and Class B common stock. For each share of Class A common stock held, stockholders were to receive an additional 3 shares of Class A common stock, For each share of Class B common stock held, stockholders were to receive an additional 3 shares of Class B common stock. On January 18, 2018, the Company’s Board of Directors decided to cancel the proposed 4-for-1 forward stock split.

On January 5, 2018, the Securities and Exchange Commission announced the temporary suspension of trading in the Company’s securities from January 8, 2018 to January 22, 2018 because of (i) questions regarding the accuracy of assertions, since at least September 2017, by the Company in filings with the Commission regarding the Company’s business operations; and (ii) concerns about recent, unusual and unexplained market activity in the Company’s Class A common stock since at least November 2017.

On March 31, 2018, the Company’s Board of Directors approved issuing 150,000 Class C common unregistered restricted shares to Global Alliance Securities for consulting services. 150,000 Class C common shares were issued on August 30, 2018. The $30,000 estimated fair value of the 150,000 shares of Class C common stock (using a price of $0.20 per share) was expensed in the three months ended August 31, 2018.

NOTE 8 - RELATED PARTY TRANSACTIONS

AsAt ~~described~~August in31, ~~Note 10~~2016, the Company was obligated to Mr. Mark DeStefano (“DeStefano”) for a $50,000 note payable and $26,981 for payments made on behalf of the Company. Subsequently, Mr. DeStefano advanced $1,285 to the Company. During the three ~~months~~ months ended November 30, 2016 the Company satisfied these obligations. DeStefano had voting control of the Company from June 2014 ~~(see Note 10)~~ to October 24, 2016 (when the Company purchased from DeStefano the 1,000,000 shares of Preferred Stock for $33,735) through his ownership of the 1,000,000 shares of Voting Preferred Stock issued and outstanding (equivalent to 50,000,000 votes).

For the three months ended November 30, 2016, consulting fees paid to former related parties consists of a total of $15,000 paid to the two then directors of the Company and $10,000 paid to an entity controlled by DeStefano.12

Commencing March 2017, the Company has been using office space provided by an affiliate of UBI Blockchain Internet, LTD. (Hong Kong) (“UBI Hong Kong”) at a monthly rent of 22,100 Hong Kong Dollars (approximately $2,~~816~~825 at the ~~May~~November 3130, 2018 exchange rate) per month. For expediency reasons, the Company also uses bank accounts in the name of UBI Hong Kong to collect cash receipts and expend cash disbursements relating to Company operations. UBI Hong Kong owns 30,000,000 shares of the Company’s Class A common stock.

InDuring the ~~nine~~three months ended ~~May~~November 3130, 2018, Tony Liu, chief executive officer of the Company, advanced or paid a total of $1413,~~047,943 of~~054 of expenditures on behalf of the Company. As of ~~May~~November 3130, 2018, the total amount due to Tony Liu was $12,~~555~~365,~~341~~721. The amount due to Tony Liu for these expenditures is interest bearing at a rate of 7% per annum. $2434,~~024~~781 and $5210,~~869~~826 interest expense was ~~accrued~~ accrued for the three ~~and nine~~ months ended ~~May~~November 3130, 2018 and 2017, respectively. As of ~~May~~November 3130, 2018, accrued interest amounted to $63126,~~201~~250. The advances and related accrued interest are due on demand.

Included in accounts payable and accrued liabilities at November 30, 2018 and August 31, 2018 is accrued salary due to Tony Liu, chief executive officer, $63,154 and $62,744, respectively.

NOTE 9 - PROVISION FOR INCOME TAXES

The Company accounts for income taxes under FASB Accounting Standard Codification ASC 740 “Income Taxes”. ASC 740 requires use of the liability method. ASC 740 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. Deferred tax assets and liabilities at the end of each period are determined using the currently enacted tax rates applied to taxable income in the periods in which the deferred tax assets and liabilities are expected to be settled or realized.

As of ~~May~~November 3130, 2018, and August 31, ~~2017~~2018, the Company had net operating loss carry forwards of approximately $23,~~500~~174,000 and $12,~~444~~883,000, respectively, as follows:

Tax Jurisdiction	~~May~~November 3130, 2018		August 31, ~~2017~~2018
United States	$	1,~~225~~351,000	$	1,~~126~~296,000
Hong Kong		~~947~~1,061,000		2855,000
China (UBI Shenzhen)		~~328~~762,000		~~316~~732,000
Total	$	23,~~500~~174,000	$	12,~~444~~883,000

United States net operating losses prior to 2018 may be carried forward to reduce future years taxable income for 20 years; United States net operating losses after 2017 may be carried forward indefinitely. Hong Kong net operating losses may be carried forward indefinitely. China net operating losses may be carried forward for 5 years. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements as their realization has not been determined likely to occur. Also, due to the change in control, there are annual limitations on future United States net operating loss carry forward deductions.

~~At May 31, 2018 and August 31, 2017, deferred tax assets consisted of:~~13

	May 31, 2018			August 31, 2017
Net operating loss carry forwards	$	495,505		$	473,511
Valuation allowance		(495,505	)		(473,511	)
Deferred tax assets - net	$	-		$	-

At November 30, 2018 and August 31, 2018, deferred tax assets consisted of:

As a result of the tax Cuts and Jobs Act enacted on December 22, 2017, the United States corporate income tax rate was reduced from 35% to 21% effective January 1, 2018. Accordingly, we reduced our deferred income tax asset relating to our United States net operating loss carryforward (and the valuation allowance thereon) by approximately $166,000 on December 31, 2017.

	November 30, 2018			August 31, 2018
Net operating loss carry forwards	$	666,540		$	587,617
Valuation allowance		(666,540	)		(587,617	)
Deferred tax assets - net	$	-		$	-

As a result of the Tax Cuts and Jobs Act enacted on December 22, 2017, the United States corporate income tax rate was reduced from 35% to 21% effective January 1, 2018. Accordingly, we reduced our deferred income tax asset relating to our United States net operating loss carryforward (and the valuation allowance thereon) by approximately $243,280 on December 31, 2017.

All tax years remain subject to examination by the respective tax authorities.

NOTE 10 - ~~NOTES~~DEVELOPMENT ~~PAYABLE – Former Related Party~~AGREEMENTS

~~On April 4, 2014, the Company issued a One-year Promissory Note (“the Note”) in the amount of $50,000 to Mark DeStefano (“DeStefano) (see Note 8).~~ The ~~Note~~Brewing bore interest at 12% percent per annum with interest due each month. In the event that interest was not paid within three days from the time it was due the Note was to be considered in default and was to be fully due and payable. Additional consideration for the Note included the Chief Executive Officer of the Company ~~giving the note holder his voting proxy for all of the shares he held with the exception of voting on a tender offer or a sale of the Company’s assets. As of May 8, 2014, the Note was in default.~~Agreement

OnIn ~~May~~August 52018, ~~2014,~~ the Company ~~issued~~entered into a ~~second~~development ~~One-Year~~agreement, ~~Promissory~~by ~~Note~~and among the Company, Heilongjiang Province TongFangZhuoXin Brewing Co., Ltd. (“the ~~Second~~“Brewing ~~Note~~Company”) inand ~~the~~Global ~~amount~~Blockchain ofCooperation ~~$20~~Alliance,~~000~~ ~~to the~~dated ~~same~~August ~~stockholder~~26, ~~noted~~2018 ~~above.~~(the ~~The~~“Brewing Company ~~Second~~Agreement”). ~~Note~~Pursuant ~~was~~to ~~issued~~the ~~with~~terms of the ~~restriction~~Brewing ~~that~~Company Agreement, the ~~funds~~Company beagreed ~~used~~to ~~specifically~~provide to ~~pay~~ the Brewing Company’s ~~Patent~~blockchain ~~Counsel~~based technology and software for ~~fees~~the tomanagement ~~finalize~~of ~~certain~~the ~~patent~~Brewing ~~filings~~Company’s ~~and~~manufacturing ~~was~~process. ~~secured~~In byexchange for ~~all~~the ~~patents~~services and ~~patent~~technology ~~applications held~~provided by the Company., ~~The~~the ~~Second~~Brewing ~~Note~~Company ~~was~~agreed to ~~bear~~pay ~~interest~~to atthe ~~12%~~Company ~~percent~~a ~~per~~total ~~annum~~of ~~with~~RMB ~~interest~~7,000,000 (approximately ~~due~~$1,007,808), ~~each~~which ~~month~~is payable over the term of the Brewing Company Agreement in a series of milestone payments. The InCompany received the ~~event~~initial payment of RMB 400,000 (RMB 388,350 net of tax or approximately $56,223) on September 30, 2018. ~~that~~The ~~interest~~balance ~~was~~is ~~not~~payable ~~paid~~in ~~within~~a ~~three~~series ~~days~~of 8 payments ranging from ~~the~~RMB 300,000 (approximately $43,192) to RMB 1,500,000 (approximately $215,959) from time itto ~~was~~time as each milestone is completed over a period of 27 months, with the final payment being due on or before December 31, 2020. Any disputes between the ~~Second~~parties ~~Note~~are ~~would~~to be ~~considered~~submitted to the Beijing International Arbitration Center. The Brewing Company Agreement provides for a breach penalty in ~~default~~an ~~and~~amount ~~would~~equal to 5% of the contract amount in the event that beeither ~~fully~~party ~~due~~defaults ~~and~~in ~~payable~~its obligations pursuant to the Brewing Company Agreement.

~~On June~~The 6,Company ~~2014,~~recognizes ~~the~~revenue ~~Company~~under ~~received~~this agreement ~~notices~~as ~~that~~its itperformance ~~was~~obligations inunder ~~default~~each milestone of the ~~two~~agreement ~~Promissory~~are ~~Notes described above~~completed. ~~Rather~~At ~~than~~November ~~default on~~30, ~~the Notes~~2018, the Company ~~issued 1,000,000 shares of $0.001 par value Voting Preferred Stock in exchange for Notes Payable totaling~~’s ~~$20,000~~performance ~~plus~~obligations ~~forgiveness~~ of ~~interest~~the ~~totaling~~Phase $1~~,900.~~ ~~Additionally,~~Period ~~the~~1 ~~Company~~milestone ~~agreed~~(relating to ~~designate with~~ the ~~State~~RMB of400,000 ~~Nevada~~initial ~~Secretary of~~payment) ~~State~~have ~~that~~been ~~each share of preferred carries the voting power of 50 common shares~~completed. ~~Finally, the shareholder agreed to cancel~~At ~~the~~November ~~shares upon full payment of the $50~~30,~~000~~ ~~Note~~2018, ~~without~~the ~~accrued~~Company ~~interest~~has ~~and~~no ~~the~~contract ~~sale~~assets ofor ~~five~~contract ~~units~~liabilities ofrelating ~~the~~to ~~MDU~~this agreement.

~~In October~~The ~~2016,~~Hotel ~~the~~Group ~~$50,000 note payable was satisfied.~~Agreement

16In August 2018, the Company entered into a development agreement, by and between the Company and Harbin Madieer Hotel Group Co., Ltd. (the “Hotel Group”), dated August 26, 2018 (the “Hotel Group Agreement”). Pursuant to the terms of the Hotel Group Agreement, the Company agreed to provide to the Hotel Group a blockchain based system for hotel management. In exchange for the services and technology provided by the Company, the Hotel Group agreed to pay to the Company a total of RMB 1,000,000 (approximately $143,973) which is payable over the term of the Hotel Group Agreement in a series of milestone payments. The initial payment of RMB 400,000 (RMB $388,350 net of tax or approximately $56,222) was received on November 12, 2018. The balance is payable in a series of 3 payments ranging from RMB 300,000 (approximately $43,192) to RMB 400,000 (approximately $57,589) from time to time as each milestone is completed, over a period of 11 months, with the final payment being due on or before July 31, 2019. Any disputes between the parties are to be submitted to the Beijing International Arbitration Agency or a People’s Court of the Hotel Group’s location. The Hotel Group Agreement provides for a breach penalty in an amount equal to 5% of the contract amount in the event that either party defaults in its obligations pursuant to the Hotel Group Agreement.

~~NOTE~~The Company recognizes revenue under this 11agreement –as ~~OTHER~~its ~~INCOME~~performance ~~AND~~obligations ~~EXPENSE~~under each milestone of the agreement are completed. At November 30, 2018, the Company’s performance obligations of the Phase 1 Period 1 milestone (relating to the RMB 400,000 initial payment) have been completed. At November 30, 2018, the Company has no contract assets or contract liabilities relating to this agreement.

~~During the three months ended November 30, 2016, the Company settled a bank overdraft of $942 for $370. This settlement resulted in income of $572.~~14

OnNOTE ~~January~~11– ~~27,~~COMMITMENTS ~~2017,~~AND the Company entered into a Settlement Agreement with a former landlord satisfying a $35,868 accrued liability for $4,100. This settlement, along with an arrangement with another vendor, resulted in other income of $47,003.CONTINGENCIES

NOTE 12 – COMMITMENTS AND CONTINGENCIES

The Hong Kong Polytechnic University Project

On January 10, 2018, the Company announced that the Hong Kong Special Administrative Region (“HKSAR”) approved in principle a grant of up to HK$3,018,750 (approximately $~~385~~386,000) to assist in financing a project entitled “Blockchain-Based Food and Drug Counterfeit Detection and Regulatory System” (“the HKPU Project”) to be jointly developed by UBI Hong Kong and The Hong Kong Polytechnic University (“HKPU”). The related agreement also provides for UBI Hong Kong to contribute up to HK $3,018,750 (approximately $~~385~~386,000) to the project cost in installments with the first installment of HK$561,198 (approximately $72,000) due upon HKSAR’s signing of the agreement (which occurred on January 5, 2018). UBI Hong Kong, owned and controlled by Tony Liu, is the largest Class A Common Stock shareholder of UBI Blockchain Internet, Ltd., (Delaware). Although the Company does not own or control UBI Hong Kong, UBI Hong Kong, ~~our principal stockholder,~~ entered into an Assignment Agreement with UBI Delaware on May 1, 2018, ~~whereby~~ whereby UBI Hong Kong assigned all of its rights, plans, ideas, tangible assets, intangible assets and intellectual property under ~~the~~ the HKPU Project agreement to UBI Delaware, in order for UBI Delaware to commercialize the technology being developed. The project is expected to be completed by November 14, 2019. In a series of two payments made by UBI Hong Kong on January 12, 2018 and January 16, 2018, UBI Hong Kong paid its first installment of a total of HK$561,198 (approximately $7172,000) to HKPU. On February 1, 2018, HKSAR paid its first installment of HK $561,198 (approximately $7172,000) to HKPU. At this point, the project is progressing on track, and the parties believe the established budget will be sufficient to complete the project.

The agreement also provides for UBI Hong Kong to pay the remaining HK $2,457,552 (approximately $314,000) of its installments as follows: HK $687,934 (approximately $88,000) by April 1, 2018; HK$687,934 (approximately $88,000) by October 1, 2018; HK $687,934 (approximately $88,000) by April 1, 2019 and HK$393,750 (approximately $50,000) within three months of the completion of the HKPU Project. On May 11, 2018, UBI Hong Kong paid HKPU a second installment of HK $643,647 (approximately $82,000). On May 24, 2018, HKSAR also paid HKPU a second installment of HK $643,647 (approximately $82,000). While UBI Hong Kong does not have the financial wherewithal to pay current installments under the agreement as due, Tony Liu has personally agreed and been able to provide funding as necessary for both operations of the Company and obligations due under the agreement.

17The agreement also provides for the HKSAR to pay the remaining HK $2,457,522 (approximately $314,000) of its installments periodically within 30 days after the acceptance by the Commissioner of Innovation and Technology (“CIT”), an agency of the HKSAR, of certain Progress Reports to be submitted periodically by HKPU. The agreement provides that HKPU should provide CIT the first written Progress Report in a format acceptable to CIT covering from the Commencement Date to August 31, 2018 to be submitted on or before September 30, 2018. The first written progress report was timely submitted by UBI Hong Kong and HKPU to CIT. The agreement imposes no penalties on UBI Hong Kong should it fail to make any of its installment contributions except that HKSAR principally has the right to cease their installment contributions if UBI Hong Kong fails to make its installment contributions. HKSAR may terminate the agreement if UBI Hong Kong fails to make any of its installment contributions. Further, if any of the parties are in breach of the terms of the agreement or fail in a material way to progress in accordance with the Project Proposal, HKPU shall on demand by the government pay to the Government an amount equivalent to the funds or portion thereof released for the Project.

The agreement also provides for the HKSAR to pay the remaining HK $2,457,522 (approximately $314,000) of its installments periodically within 30 days after the acceptance by the Commissioner of Innovation and Technology (“CIT”), an agency of the HKSAR, of certain Progress Reports to be submitted periodically by HKPU. The agreement provides that HKPU should provide CIT the first written Progress Report in a format acceptable to CIT covering from the Commencement Date to August 31, 2018 to be submitted on or before September 30, 2018. While no written Progress Reports have yet been required or provided to CIT, periodic telephone conversations with CIT have occurred between CIT, HKPU, and the Company from time to time concerning HKPU Project’s progress. The agreement imposes no penalties on UBI Hong Kong should it fail to make any of its installment contributions except that HKSAR principally has the right to cease their installment contributions if UBI Hong Kong fails to make its installment contributions. HKSAR may terminate the agreement if UBI Hong Kong fails to make any of its installment contributions. Further, if any of the parties are in breach of the terms of the agreement or fail in a material way to progress in accordance with the Project Proposal, HKPU shall on demand by the government pay to the Government an amount equivalent to the funds or portion thereof released for the Project.

Project Summary

The goal of this project is to provide a comprehensive solution to the worldwide problem of counterfeit medicines. Leveraging latest techniques the team ~~want~~wants to develop a low-cost, scalable, secure system for: (1) Manufacturers to record necessary data of the drugs during their production and transportation; (2) Distributors to trace the drugs; (3) Auditors to inspect all data; and finally (4) Consumers to verify the authenticity of the purchased product. This platform will provide suppliers of food and drug products a safety control system to determine if there was a break in the supply chain. It will identify if a product was substituted with a counterfeit or inferior product. It will help suppliers of perishable food products, reduce spoilage by tracking food shipments in the supply chain to the final consumer.

In February 2018, UBI Hong Kong performed a test at the offices of Guangxi Houde Mega Health Enterprise (“Guangxi”), a medical products company, of the e-commerce “alpha” platform (using simulated test data provided by Guangxi). Guangxi is owned 70% by Star Bright International Enterprise Ltd. Star Bright is a stockholder offering 5,000,000 resale Class C common shares in this registration statement. The test identified some technical issues that need to be addressed; the team is currently preparing for a second test, the second test, originally scheduled for June 2018, will not be scheduled until the team believes the test will be successful. The e-commerce platform will provide a digital shared accounting ledger that would make it possible to trace back a product to the very origin of the raw material used.15

In February 2018, UBI Hong Kong performed a test at the offices of Guangxi Houde Mega Health Enterprise (“Guangxi”), a medical products company, of the e-commerce “alpha” platform (using simulated test data provided by Guangxi). Guangxi is owned 70% by Star Bright International Investment Enterprise Limited, owner of 5,000,000 shares of Company Class C Common Stock (see Note 7). The test identified some technical issues that need to be addressed; the team is currently preparing for a second test, the second test, originally scheduled for June 2018, will not be scheduled until the team believes the test will be successful. The e-commerce platform will provide a digital shared accounting ledger that would make it possible to trace back a product to the very origin of the raw material used.

Once a working model of a platform is successfully operational, the Company plans to license the technology to larger food and drug third party customers, in which case the licensee can use it in accordance with the license agreement; and the Company also intends to provide the technology, when commercial ready, to third party suppliers as a paid service.

The agreement provides that the equipment acquired from the HKPU Project will belong to HKPU, who is also identified as the Beneficiary of the grant for the project and is required to provide CIT with interim and a final accounting for the proceeds of the grant as well as monies advanced by UBI Hong Kong whether the project is successful or not. While HKPU, as the Beneficiary, is provided discretion on how income arising from the intellectual property rights from the Project Materials (including among other things computer software/programs, technical materials, models, documents and materials compiled developed, produced or created by or on behalf of the Beneficiary – the “platform”) and Project Result is to be allocated, UBI Hong Kong is the sole and absolute beneficial owner (has title to) of all of the intellectual property rights which would include the platform if successfully completed under the project.

While HKPU receives full legal and equitable title and interest in any and all of the equipment procured by the Beneficiary, the agreement does not discuss whether HKPU can discontinue its own performance in the event that either HKSAR or UBI Hong Kong fail to make the required payments. However, without funding no one would expect that HKPU would be obligated to continue its performance.

The agreement also has a provision whereby the HKSAR can terminate the grant under certain conditions. These conditions include, among other things, ethical misuse of funds received under the grant or violations of other requirements under the grant. This would include UBI Hong Kong’s failure to meet its general financial obligations as due or go into liquidation. In the event of termination, the HKSAR has the right to suspend payment under the grant or require that amounts previously paid by it be refundable under the grant.

The Company expects to use the technology learned from the HKPU Project to help it develop and market a platform system for application to control and manage the safety of food and drugs. Pursuant to an understanding with UBI Hong Kong, the Company is responsible for the installments due and other costs relating to the HKPU Project paid by UBI Hong Kong. These costs are expected to be paid by UBI Hong Kong from loans received from the Company’s CEO Tony Liu. The Company ~~expects~~records ~~to record~~ these costs as research and development expenses and increases in amounts due to Tony Liu until such time as a “technologically feasible” working model of the platform has been successfully produced.

The Company plans to commercialize our blockchain technology, by selling suppliers of food and drug products a blockchain technology platform to track the shipping of their products from itits source to the final consumer with tamper-resistant digital records that replaces the current related shipping paperwork. There are two ways we plan to commercialize the technology: 1) to license the technology to third parties, in which case the licensee can use it in accordance with the license agreement; and 2) UBI to provide the technology to third party suppliers (the supplier will pay for each use). The goal is to license our blockchain technology to streamline record-keeping for the food and drug supply chain. We also plan to provide blockchain technology, when commercial ready, to suppliers as a paid service. Our goal is to design a blockchain tracking system that eliminates counterfeit drug products being substituted in the supply chain. And, with regards to food products where lost or delayed shipments causes perishable goods lying in wait to spoil, our blockchain tracking is being designed to help expedite and monitor physical transportation. It is management’s goal to have this technology ready for commercialization soon after the fiscal year ending August 31, 2019.

Management believes that blockchain technology along with the capabilities of tamper resistance products can help bring about new safety standards for the health industry. This makes blockchain technology worthy of our research and investment. It is for this reason management made a decision then to establish a company to research and develop blockchain technology. In order to achieve its goals, management is working to design a product tracking system, where every step a product takes in its supply chain is recorded, time-stamped and monitored to protect the integrity of the product(s) being shipped from it source to the final consumer. This is being accomplished by tracing the movement of the product from its origin to its final consumer. Utilizing blockchain technology, every time the product moves, its location is recorded and time-stamped, and a shared accounting ledger can be reviewed to determine if there was a break in the supply chain, to see if the product was substituted with a counterfeit or inferior product.16

Management believes that blockchain technology along with the capabilities of tamper resistance products can help bring about new safety standards for the health industry. This makes blockchain technology worthy of our research and investment. It is for this reason management made the decision to establish a company to research and develop blockchain technology. In order to achieve its goals, management is working to design a product tracking system, where every step a product takes in its supply chain is recorded, time-stamped and monitored to protect the integrity of the product(s) being shipped from its source to the final consumer. This is accomplished by tracing the movement of the product from its origin to its final consumer. Utilizing blockchain technology, every time the product moves, its location is recorded and time-stamped, and a shared accounting ledger can be reviewed to determine if there was a break in the supply chain, to see if the product was substituted with a counterfeit or inferior product.

UBI’s business strategy is to incorporate the research and application of blockchain technology, Internet of Things (“IoT”), pharmaceutical and food products, which together, we refer to as IBSH platform. We have hired professional and technical personnel to develop a working platform. With the development and research on the platform, we plan to build a blockchain based safety control system, tentatively named “UBI Security Shield”, with its first application to be used for food and drug safety

Lease Commitments

In September 2017, UBI Shenzhen entered into two lease agreements for office space in Shenzhen China. The first lease provides for monthly rent of RMB 12,353, or approximately $1,~~928~~778 per month, and expires September 2020. The second lease provides for monthly rent of RMB 8,964, or approximately $1,~~399~~291 per month, and expires September 2019.

19As of November 30, 2018, the future minimum lease payments under non-cancelable operating leases were:

As of May 31, 2018, the future minimum lease payments under non-cancelable operating leases were:

Year ending November 30, 2019	$	34,246
Year ending November 30, 2020		17,780
Total	$	52,026

Three months ending August 31, 2018	$	9,981
Year ending August 31, 2019		39,924
Year ending August 31, 2020		24,535
Year ending August 31, 2021		1,928
Total	$	76,368

For the three months ended November 30, 2018 and 2017, total rent expense was $32,653 and $16,621, respectively.

For the three and nine months ended May 31, 2018, total rent expense was $25,359 and $65,049, respectively.

Right of Rescission Contingency

The offer and sale of the 25,000,000 Class C Common Shares for the acquisition of UBI Shenzhen may have been in violation of the rules and regulations under the Securities Act and the interpretations of the SEC. The possible violation involves whether the Company conducted a public offering without providing the former UBI Shenzhen shareholders with a registration statement declared effective by the SEC. If a violation of the Section 5 of the Securities Act did in fact occur, anyone who acquired Class C Common Shares at a price based on an evaluation of $0.20 per share would have a right to rescind the purchase. The Securities Act generally requires that any claim brought for a violation of Section 5 of the Securities Act be brought within one year of the violation. If all the shareholders who acquired Class C Common Shares for their exchange in the ownership of UBI Shenzhen demanded rescission within that one-year period and prevailed in their claims, we would behave potentially been obligated to repay approximately $5,000,000.

In the opinion of management and company counsel, the likelihood of any of the former UBI Shenzhen shareholders making a claim for a violation of Section 5 of the Securities Act is remote because the effected shareholders are all Chinese citizens who have a close knit relationship with each other and who all voted in favor of the Company’s acquisition of UBI Shenzhen. None of these effected shareholders have made any claim to date and the one -year period that they ~~have~~had to bring a claim ~~expires~~expired August 29, 2018.

20NOTE 12 – SUBSEQUENT EVENTS

~~Item~~On 2.December -10, ~~Management’s~~2018, ~~Discussion~~UBI ~~and~~Hong ~~Analysis~~Kong ofPaid ~~Financial~~HKPU ~~Condition~~a ~~and~~third ~~Results~~installment of ~~Operations~~HK$ 653,647.55 (approximately $84,000) required under the HKPU project agreement (see Note 11).

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains forward-looking statements. When used in this Quarterly Report on Form 10-Q, the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” and similar expressions identify forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in any forward-looking statements are reasonable, these plans, intentions, or expectations may not be achieved. Our actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied, by the forward-looking statements contained in this Quarterly Report on Form 10-Q. Important factors that could cause actual results to differ materially from our forward-looking statements are set forth in this Quarterly Report on Form 10-Q. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this Quarterly Report on Form 10-Q, except as required by federal securities laws, we are under no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties.

In this Quarterly Report on Form 10-Q references to “UBI Blockchain Internet, Ltd.,” “JA Energy,” “UBI Blockchain Internet, Ltd., formerly known as JA Energy,” “UBI,” “the Company”, “we,” “us,” and “our” refer to UBI Blockchain Internet Ltd. ~~(a Delaware Company).~~

~~Company~~Corporate History

The Company was ~~organized~~incorporated in Nevada on August 26, 2010, ~~(Date of Inception)~~ under the ~~laws~~name ~~of the State of Nevada, as~~ “JA Energy.,” ~~The Company was incorporated~~ as a subsidiary of Reshoot Production Company, a Nevada corporation., ~~Reshoot Production Company was~~ incorporated October 31, 2007. In May, ~~and~~2011, atReshoot ~~the~~Production ~~time~~Company ofspun ~~spin~~ off ~~was listed on~~ the ~~Over-the-Counter~~Company ~~Bulletin~~to its ~~Board~~shareholders.

From August 2010 to May 2014 the Company was in the business of designing a suite of modular, self-contained, fully automated, climate controlled units for distributed production of energy. While some of these products were proven to be technologically viable, none were ever developed to the point where they were ready for introduction to the marketplace.

OnIn orOctober ~~about~~2014, ~~September~~pursuant 30to the terms of an Irrevocable Asset and Liability Exchange Agreement, dated as of October 15, 2014, by and among the ~~Board~~Company, ofJames ~~Directors~~Lusk, ~~approved~~Mark DeStefano and T.J. Jesky, the ~~formation~~Company transferred all of aits ~~new~~assets ~~company~~and ~~called~~liabilities to its wholly owned subsidiary, Peak Energy Holdings, a Nevada corporation, ~~where~~(“Peak”) ~~each~~and ~~shareholder~~Peak inissued to the Company’s shareholders, ~~received~~ one share of ~~common of~~ Peak ~~Energy~~common ~~Holdings~~stock for each share of common stock owned in the Company and one share of ~~preferred~~Peak preferred stock ~~of Peak Energy~~ for each share of preferred ~~share~~stock owned in the Company~~. As~~ ~~part of~~ (the ~~transaction, the Company spun~~“Spin-~~off all of its assets and liabilities into Peak Energy~~Off”). ~~Further,~~Following the ~~spin~~Spin-~~off~~Off, ~~subsidiary operated~~Peak operated as an independent entity separate ~~entity~~ from the Company with new management ~~operating the current core business of Peak Energy for the benefit of the original stockholders~~. The ~~effect~~Spin-Off ~~of this action~~ allowed the Company to explore new business opportunities without the burden of the assets and liabilities on the corporate books.

In September 2016, the Company established its headquarters in Hong Kong, and issued 30,000,000 shares of unregistered restricted Class A Common Stock, 6,000,000 shares of unregistered restricted Class B Voting Common Stock, which carries a voting weight equal to ten (10) Common Shares, and 40,000,000 shares of unregistered restricted Class C Common Stock to UBI Blockchain Internet, LTD (“UBI Hong Kong”), in exchange for $200,000. UBI Hong Kong is beneficially owned and controlled by Tony Liu our CEO and as a result of the transaction UBI Hong Kong and Tony Liu became controlling shareholders of the Company. Thereafter, the Company’s business focus was dedicated to the application of the blockchain technology to safety issues arising out of counterfeit and inferior substitute products and services in the Chinese health industry.

On November 21, 2016, the Company changed its corporate name from JA Energy (“JA”) to UBI Blockchain Internet, LTD, and changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion about which the Company adopted a new certificate of incorporation under the laws of the State of Delaware after UBI acquired a controlling equity in JA and this transaction was treated as a reverse merger for accounting purposes.

Acquisition of UBI Shenzhen Cross Border E-commerce Co., formerly, Shenzhen Nova Cross-Border E-commerce, Ltd. (“UBI Shenzhen”)

On May 16, 2017, the Board of Directors of the Company ratified and approved an Acquisition Agreement between the Company and UBI Shenzhen. Under the terms of the Agreement, UBI acquired 100% ownership of UBI Shenzhen in exchange for the issuance to UBI Shenzhen’s shareholders of 25,000,000 shares of UBI unregistered restricted Class C common stock. Upon completion of the acquisition, UBI Shenzhen became a 100% owned subsidiary of UBI.

About UBI Shenzhen

UBI Shenzhen was formed as a private Shenzhen Chinese company on May 26, 2016, under the name Nova Cross-Border E-Commerce, and operates an online store in China selling a wide range of products including maternal and infant products, cosmetics, wine, household goods, digital and luxury products via its Oya Mall, a cross-border e-commerce platform. This website entered into operation in April, 2017.

In April 2018, UBI Shenzhen changed its name from Shenzhen Nova Cross-Border E-commerce, Ltd. to UBI Shenzhen Cross Border E-commerce Co. UBI Shenzhen is registered in Qianhai Free Trade Zone, China. The website changed its name from www.oyamall.com to www.hihealth8.com in April 2018. On September 1, 2018, the website became operational as a marketplace for customers can buy products including, food, non-prescription medicine, skin care products, etc.

UBI Shenzhen’s operations include, but are not limited to:

	●	Researching and developing business opportunities unique to a Chinese customer base

	●	Building corporate infrastructure and administration

	●	Integration of multiple technologies and programs

	●	Building Business Relationships

	●	Human resource staffing

	●	Training personnel

	●	Equipment procurement

	●	Building the corporate website

	●	Developing marketing strategies to capitalize on commercialization activities

	●	Establish and maintain strategic collaborations with product suppliers

	●	Obtain financing to implement the business activities

Overview

UBI Blockchain Internet is a company focused on research & development and application of blockchain technology, including the combination of Internet of Things (“IoT”) and other high-tech technologies to health industry issues prevalent in China.

UBI’s business focus on blockchain technology is based on management’s persistent exploration and pursuit of solutions to prevent and eliminate the health industry issues prevalent in China, i.e. the safety issues of products and services caused by counterfeits and inferior substitutes resulting in harm to human lives. Entering the 21^st century, with the rise of technology innovation and progress, especially with the emergence of the blockchain technology, our management determined that an opportunity was available to discover and apply blockchain based solutions to the problem of safety and counterfeits in health products and services.

UBI has established a dedicated R&D team, developed in cooperation with the Hong Kong Polytechnic University (HKPU), and has obtained approval from the Hong Kong government for the blockchain project, titled “Blockchain-Based Food and Drug Counterfeit Detection and Regulatory System”, coded as “UIM/331”. Information related to this project is publicly available on Hong Kong Special Administration Region (“HKSAR”)’s official website at http://itf.gov.hk/l-eng/Prj-eng/Prj_Search_Index.asp. At the same time, UBI cooperates with blockchain experts and technical teams from Germany, India and other countries and regions, committed to the development of blockchain and its application in health industry.

On August 15-16, 2018, UBI together with other founders and sponsors, organized a Global Blockchain Cooperation Alliance Forum at the Company’s Hong Kong Cyberport headquarters. More than 200 people who are blockchain experts, scholars, lawyers, financiers and entrepreneurs, from universities, research institutes, and media from over 20 countries and regions attended the event. UBI introduced and demonstrated the results of its blockchain development and application at the conference, and proposed the concept “2018, the genesis of applied blockchain technology.”

UBI is optimistic about blockchain technology because blockchain is an innovative form of combination of computer skills such as distributed data storage, point-to-point transmission, consistent mechanisms, and encryption algorithms. Owing to its unique characteristics such as being traceable and modification resistant, decentralized and open transparent. Blockchain technology can be used to effectively address the safety and quality issues of products and services in the health industry. Monitored by the technology, the factitious factors are eliminated. The integration of Internet of Things “IoT”, Virtual Reality “VR”, Augmented Reality “AR”, Artificial Intelligence “AI”, and other technologies will greatly improve the application level and effectiveness.

The UBI blockchain system is based on the Ethereum framework and adopts the consortium blockchain (as defined below). This is the first generation and the first product of UBI as well. In early September 2018, the product was introduced to the market for promotion. UBI defines the consortium blockchain as follows: 1. Important product quality data must be stored in the blockchain to ensure its traceability and resistance to modification; 2. Only authorized organizations or individual are allowed to enter product data in the blockchain (characteristics of private chain); 3. Block Data in the blockchain is completely open and accessible to the public (characteristics of public chain). 4. Smart contracts are widely used in application scenarios.

UBI has developed a plan dedicated to the long-term development and application of blockchain technology to the Chinese health care industry. The Company’s goal is to reshape the trust system and innovate the business model for the Chinese health care industry by building the UBI blockchain based Global Health Chain system. This goal has three important parts: the first one is Kang-Chain Network, which will be an internet-based blockchain network capable of worldwide coverage, which we believe will enable connections through the internet between natural persons, medical institutions, and providers of health products and health services. We may also describe it as a value oriented or trust internet, to differentiate it from the current information internet. A trust system, service concept, and value orientation can be built for the safeguard of human lives and health quality from the perspective of super technology and cutting-edge thinking. We believe this future model for health differentiates itself from the current health practice in that it is built on trust and safeguard to provide a professional, targeted, flexible, easy to use, peer to peer, group to group, and safe health world that is writable and readable. We believe that the Kang-Chain Network will connect everyone, regardless the location in the world, to have all one’s needs of health satisfied. We believe that the Kang-Chain Network has the potential to entirely change the health world as it is known to us today. The second part consists of the Kang-Kang-Chain Cloud, which will fundamentally change people’s fear for and concerns about “clouds”. What is more important is that it will protect data privacy with clustered blockchain technology, so as to truly realize the data safety, privacy, permit based share, value, and socialization. Disconnected, and fragmented health data can be active and integrated with a humane premise, hence making it possible a human shared wealth to serve the human health. Kang Chain Cloud establishes a convenient cloud storage, a private safe, and information exchange of health data and information for individuals. The third part is Kang-Chain Community. Exchange and transactions between people used to be simple. However, along with the emergence of residual value, the trust between people started to disappear. People have worked hard to find a mechanism to get the lost trust back. People did not realize that the mechanism they were looking for had deviated from their original intention until today. Peer to peer is forthright and simple. This is exactly one of the essential characteristics of the blockchain technology, and the one that makes the disruption of reality and return to the nature possible. UBI believes the peer to peer business model will replace the current ones, and will work as a catalyst for the new communities and new business models. This also reflects the social progress and development, as well as the new normal of the shared demand, shared value, shared interest, and mutual reliance. The satisfaction between supply and demand featuring the exchange of peer to peer, group to group, and zero distance will naturally make the cost of exchange down to zero, value and speed maximized, and trusted. The innovative Kang Chain Community will be the highlight of the UBI global public health chain. Kang Chain Community is a commercial community formed out of an innovative model based on Kang Chain Network, and Kang Chain Cloud. This is a voluntary consumer community of the new era built on mutual understanding and trusting with their common needs and shared values.

Industry Trends

Blockchain techniques have shown considerable adaptability in recent years, as various market sectors have sought to find ways of incorporating capabilities into their operations. Especially since 2014, the blockchain began to be applied in the industry and commerce, and the blockchain application has entered a new era in 2018. Previously, the blockchain was mainly applied in the cryptocurrency, which kind of replaced the blockchain to mainly serve the financial industry. However, as the governments of various countries strengthen the supervision of virtual currency, the cryptocurrency circle will be restricted, and the blockchain will play an increasingly important role in industrial applications. Blockchain technology will be widely applied in the future in the fields of finance, medical health, games, copyright, sharing economy, social contact, cloud computing and other fields or industries. It will subvert today’s thinking and social models in many ways.

Application based on blockchain technology

Our management plans to focus its blockchain business on the health industry in China, and give priority to food and pharmaceuticals safety by providing effective technical systems, to prevent counterfeit foods and pharmaceuticals. With the development of blockchain technology, we can trace the entire process of food or pharmaceuticals in an all-round way in the integration of technology clusters such as IoT, VR, AR, AI, and robotics to provide manufacturers and consumers with the maximum symmetrical information exchange throughout the whole manufacturing and logistics process.

We are now in the early stages of blockchain technology, but we believe we have a good understanding of the framework design, the transition between the health industry language and the IT language, and the combination between the blockchain & the IoT and food & pharmaceutical technologies. We believe we are in a leading position and destined to have a bright future of blockchain technology.

Healthcare market

Our management believes that with the improvement of people’s living standards and the growing health awareness, the era of comprehensive health care has arrived. Following the article “Health China 2030” published by China government, we came to further understanding that healthcare, genetic testing, cell storage, precise health management, personal health data storage and analysis are increasingly recognized by humans and will become rigid demands. Traditional health care methods are being subverted. In 2015, “Health in China” was upgraded to China’s national strategy; in 2016, China launched the “Precision Medical Plan” with genetic testing technology as the main means; in 2016, “Health in China Outline 2030” plans to invest 60 billion yuan; in “The Development Plan for Emerging Industries of 2017”, genetic technology is included in National Document No. 1. In the United States, more than 5 million people receive genetic testing every year, creating a profit of 3 billion US dollars; Japan proposed the National Health Plan as early as in 1988 and nowadays the Japanese’s average life expectancy has reached 84 years old. Everybody needs health management. It is estimated that the market scale of China’s health industry will exceed 10 trillion yuan by 2020, according to China National Statistics Bureau.

On November 21, 2016, the Company changed its corporate name to UBI Blockchain Internet, LTD, and changed the state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion in connection with which the Company adopted a new certificate of incorporation under the laws of the State of Delaware.Opportunities

OnBlockchain ~~August~~and ~~29, 2017,~~ the ~~Company~~IoT ~~acquired~~are ~~100%~~technologies ~~ownership~~that ofaffect ~~UBI~~the ~~Shenzhen~~future ~~Cross~~and ~~Border~~are ~~E-commerce~~important ~~Co.,~~ways ~~Ltd.~~and ~~(“UBI~~means Shenzhen”), formerly Shenzhen Nova E-commerce, Ltd., (“Nova”) a private Shenzhen Chinese corporation in exchange for 25,000,000 unregistered restricted Class C common shares. UBI Shenzhen has yet to ~~generate~~ensure ~~any revenues, and management does not expect UBI Shenzhen will generate any revenues for~~ the ~~next~~safety ~~few~~of ~~months,~~health ~~until~~products ~~such time as the Company actively markets~~and ~~its~~health ~~website.~~services ~~In the meantime,~~ in ~~order for UBI Shenzhen to begin its business operations, UBI Shenzhen will be selling third party products. In~~ the ~~future,~~health ~~management plans to develop its own products for sale~~market. UBI ~~Shenzhen~~is ~~became a wholly owned subsidiary of~~ the ~~Company.~~first Itcompany ~~was a management decision~~ to ~~acquire~~enter UBI Shenzhen for primarily two business reasons: 1) as a separate subsidiary, once UBI Shenzhen is fully operational, management anticipates it should generate revenues and profit for the Company; and 2) this ~~acquisition provides a test model to utilize the blockchain technology the Company is developing to track drug products sold by UBI Shenzhen~~market. AsBeing ~~a test model, this will allow~~ the ~~Company~~first toone ~~see~~of ifapplying ~~the products sold through its website are substituted~~blockchain ~~with~~technology ~~counterfeit~~in ~~products before they reach~~ the ~~final~~health ~~consumer.~~industry ~~In other words, products sold through a third party consumer~~ will be ~~tracked~~help ~~using~~ the ~~Company’s~~company ~~blockchain~~position ~~technology~~and todevelop ~~see~~itself ifin ~~there~~this isfield. aThe ~~break~~access in ~~the~~this ~~supply~~market ~~chain. This will take place~~is ~~once~~of ~~the~~high ~~Company~~criteria ~~develops~~and ~~its blockchain digital tracking system~~cost. The ~~Company~~ideas ~~will~~and bebeliefs ~~able~~of tothe ~~monitor~~ UBI ~~Shenzhen~~team ~~shipments~~make ~~to the~~us ~~final~~optimistic ~~consumer,~~about ~~to determine if there has been any tampering with shipment in~~ the ~~supply chain~~future.

~~When~~In ~~UBI~~conclusion, ~~was~~we ~~first~~believe ~~formed,~~that ~~management~~the ~~established~~global ahealth ~~goal~~market ~~and~~has ~~mission~~the potential to ~~solve~~be ~~the~~huge, ~~safety~~not ~~and~~only ~~quality~~because ~~issues~~it ofhas ~~food~~tremendous ~~and~~market ~~drugs using~~dividends ~~blockchain~~formed ~~technology.~~by ~~This~~resources ~~has~~that ~~been~~people ancontinuously ~~on-going problem~~invest, ~~especially~~but inalso ~~China.~~because ~~For~~this amarket ~~number~~is ofrelated ~~years,~~to ~~management~~human ~~has~~life ~~observed~~and wellness, directly ~~first-hand,~~affecting the ~~rampant~~quality ~~counterfeit~~of human life and ~~inferior~~happiness. ~~quality~~Therefore, ~~problems~~we inwill seize the ~~Chinese~~emerging ~~health~~technology ~~industry,~~of ~~where~~blockchain ~~food~~ and ~~drugs~~the ~~constitute~~market opportunities at this particular stage, from the ~~majority~~perspective of ~~products.~~interests ~~Counterfeit~~as ~~food~~well as the responsibility for human life and ~~drug~~wellness, striving ~~products~~for ~~are~~the ~~very~~safety ~~common~~of infood and pharmaceuticals and the ~~Chinese~~safety ~~market~~of health services.

~~Management~~Our is working to develop a blockchain tracking system to detect if counterfeit products are substituted in the supply chain. Management desires that its technology is ready for commercialization soon after the twelve months ending August 31, 2019. This technology would include: (1) A tracking record system to monitor drugs during their production and transportation stages; (2) A method to inspect and review all tracking data; and (3) The ability for consumers to verify the authenticity of the purchased product. If these systems can be successfully developed they will provide suppliers of food and drug products and the final consumers a tracking system to monitor if there was a break in the supply chain. By being able to identify if a product was substituted with a counterfeit or inferior product in the supply chain, the manufacturer, supplies and final consumers benefit. This can be especially useful for suppliers of perishable food products, to reduce spoilage by tracking food shipments in the supply chain to the final consumer.Strategy

UBI will firmly and persistently dedicate itself in research, development, application and promotion of the blockchain technology to the health industry in China. We believe that this disruptive technology will profoundly affect the next ten years or even longer and will, in our opinion, benefit all humanity in the health industry. Our mission is to reshape the trust system and innovate the business model with blockchain technology. We will promote the wide application of blockchain technology in the entity industry and commerce, to explore further of the blockchain beyond its characteristics of value transfer.

Our growth strategy depends to a large extent on our ability to bring the products and technical service to potential customers in target markets. We plan to initially target the China market and gradually expand to Europe, the United States and the other countries and regions.

In order to achieve the company’s strategy, UBI has made a market development plan:

	●	By the end of 2018, the Company will further improve the development and promotion of the consortium blockchain product.

	●	Starting from 2019, the company will develop the “UBI Global Health Public Chain” with full efforts. Our strategic position and product deployment consists of “Kang-Chain Net”, “Kang-Chain Cloud” and “Kang-Chain Community” to create and provide comprehensive security services plan for human health. This plan is to be completed in three years.

	●	By the end of 2021, it will be fully promoted and applied.

Competitive Advantages

1. Excellent technical team

In its early stage of development, UBI has been cooperating with Hong Kong Polytechnic University (HKPU) and received support from the HKSAR. In this context, a joint effort in research and development participated by enterprises, universities and governments was formed with a competitive advantage. At the same time, we work closely with international blockchain experts and technical teams. We have brought together the advantages of technology and talent.

~~Commercialization~~2. Innovate blockchain application system and products through independent design and development.

WeThe ~~plan~~initial todesign ~~commercialize~~of our blockchain ~~technology,~~system byhas ~~selling~~firmly ~~suppliers of~~grasped the food and drug ~~products~~safety aissue, ~~blockchain~~an ~~technology~~industry ~~platform~~pain topoint ~~track the shipping of their products from it source to the final consumer with tamper-resistant digital records~~ that ~~replaces~~are ~~the current related shipping paperwork~~widely concerned. ~~There~~The ~~are~~technicians ~~two~~and ~~ways~~enterprise wepersonnel ~~plan to~~cooperated ~~commercialize the technology: 1)~~ to ~~license~~make ~~the~~analysis ~~technology~~and ~~to third parties~~design, inoptimize ~~which~~various ~~case~~frameworks ~~the~~and ~~licensee can use it in accordance~~solutions ~~with~~from the ~~license~~perspective ~~agreement;~~of ~~and 2) UBI to provide~~ the ~~technology~~industry tochain ~~third party suppliers (the supplier will pay for each use). The goal is to license our blockchain technology to streamline record-keeping for the food~~ and ~~drug~~ supply chain~~. We also plan to provide blockchain technology~~, ~~when~~and ~~commercial~~has ~~ready,~~created ~~to suppliers as~~ a ~~paid~~unique ~~service.~~blockchain ~~Our~~traceability ~~goal~~system isfor tosafety purpose ~~design~~— aconsortium blockchain ~~tracking system~~product. ~~that~~Meanwhile, ~~eliminates~~we ~~counterfeit~~are ~~drug~~deploying ~~products~~the ~~being~~UBI ~~substituted~~global inhealth ~~the supply~~ chain. ~~And,~~global ~~with~~system ~~regards~~based ~~to food products where~~on ~~lost~~UBI orblockchain ~~delayed~~technology ~~shipments~~world ~~causes~~widely, ~~perishable goods lying~~ in ~~wait~~order to ~~spoil,~~create ~~our~~Kang-Chain ~~blockchain~~product ~~tracking is being designed to help expedite and monitor physical transportation~~group. ~~It is management’s goal to have this technology ready for commercialization soon after the fiscal year ending August 31, 2019.~~

~~Management believes that blockchain technology along with the capabilities of tamper resistance products can help bring about new safety standards for the health industry~~3. ~~This makes blockchain technology worthy of our research and investment. It is for this reason~~ ~~management~~We ~~made~~have areliable ~~decision~~resources ~~then to establish a company to research and develop blockchain technology. In order to achieve its goals, management is working to design a product tracking system, where every step a product takes~~ in ~~its supply chain is recorded, time-stamped and monitored to protect the integrity of the product(~~China’s) ~~being~~health ~~shipped from its source to the final consumer~~industry.

~~Shenzhen~~In ~~Nova~~China, ~~E-commerce~~UBI’s management has rich experience and resources in the health industry, ~~Ltd.~~which ~~(formerly~~can ~~known~~be asused ~~“NOVA~~for scientific research and development,” ~~now~~raw ~~known~~material asproduction ~~“UBI~~bases ~~Shenzhen”)~~and other industrial chains. The company’s management is also familiar with the international pharmaceutical market and the food market.

~~On May 16, 2017, the Board of Directors of the Company ratified and approved an Acquisition Agreement with Shenzhen Nova E-commerce, Ltd~~4.~~, (“UBI Shenzhen”) formerly known as NOVA, a private Shenzhen Chinese corporation. Under the terms of the Agreement~~ ~~UBI~~A ~~acquired~~good ~~100%~~management ~~ownership of UBI Shenzhen in exchange for 25,000,000 unregistered restricted Class C common shares by UBI~~team. With the UBI Shenzhen ownership completed, the former 130 UBI Shenzhen shareholders received UBI Class C common shares based on their pro-rata ownership of UBI Shenzhen. With the NOVA acquisition completed and the name of the permit holder changed to UBI, UBI Shenzhen became a 100% owned subsidiary of UBI.

~~The~~Our ~~shareholders of UBI Shenzhen converted their ownership of UBI Shenzhen to UBIA’s Class C common shares. Following the conversion~~management, ~~UBI~~ ~~Shenzhen~~technical ~~shares~~team ~~were~~and ~~canceled.~~consulting Inteam ~~China,~~are the ~~conversion~~leading oftalents ~~shares~~and ~~requires~~professionals ~~the~~in ~~Chinese~~their ~~authorities~~fields. toThey ~~cancel~~pursue ~~UBI~~high ~~Shenzhen’s~~quality ~~registered shares~~work. OnThey ~~August~~are 29smart, ~~2017~~responsible, ~~the~~charitable ~~Chinese~~and ~~government~~gifted ~~approved~~with ~~the~~vision ~~acquisition of UBI Shenzhen. The Company issued a total of 25.000,000 shares of Class C common stock to shareholders of Shenzhen Nova E-commerce, Ltd.~~ and ~~their~~innovation ~~original UBI Shenzhen shares were cancelled by the Chinese government~~spirit.

~~About~~Target ~~Shenzhen Nova E-commerce, Ltd~~Market

~~Shenzhen~~Our ~~Nova~~current ~~E-commerce~~target ~~Ltd.~~market ~~was~~is ~~incorporated~~China, onwhere ~~May~~we ~~26,~~believe ~~2016~~food and ~~plans~~pharmaceuticals tosafety ~~operate~~has anbecome ~~online~~a ~~store~~major challenge. Counterfeit food and pharmaceuticals are very common in China, ~~selling~~due ato ~~wide~~natural ~~range~~and man-made factors. Although the safety of ~~products~~food and pharmaceuticals ~~including~~is ~~maternal~~closely ~~and~~linked ~~infant~~to ~~products,~~the ~~cosmetics,~~vital ~~wine,~~wellness ~~household~~of ~~goods~~hundreds of millions of people, ~~digital~~we believe that the laws and ~~luxury~~regulations ~~products~~governing food and pharmaceutical safety in China are not perfect or complete and may not be strictly enforced in many occasions. OnThe ~~April~~occurrence of 7poison capsule events, ~~2018~~vaccine incident, ~~NOVA changed~~ginkgo ~~its~~leaf, ~~name~~licorice totablets ~~UBI~~and ~~Shenzhen~~other ~~Cross~~major ~~Border~~drug ~~E-Commerce~~dealing ~~Co.~~and counterfeiting cases, have ~~Ltd.~~had ~~(“UBI~~serious ~~Shenzhen”).~~affects ~~UBI~~on ~~Shenzhen~~people’s ~~website became~~physical ~~operational~~and inmental ~~April 2017~~health.

Sources of Income and Pricing

UBI plans to develop a series of blockchain technology based products, such as private blockchain, consortium blockchain and public blockchain which are developed based on different application scenarios and market demands, and as well as the technical system platform. The company generates revenue and profits by providing services and effective products to potential target customers. The price will be determined by the market supply and demand. After initial promotion and marketing, the company’s products and services may have an impact on the existing healthcare industry. Looking ahead, emerging technologies will lead new trends in the health care industry, law enforcement, privacy protection, food and pharmaceuticals safety. UBI will produce good profit by providing specific blockchain solutions and systematic services.

Sales and Marketing

In the future, we will mainly market UBI blockchain system and products through online and offline store. Marketing will also be promoted through cross-border e-commerce platforms. Conference marketing and professional channel marketing will be utilized. Our products and designs also consider the overall needs of human beings and will be tailor-made for some clients. Currently, we are paying attention to the development, formation and demands of China’s “One Belt, One Road” infrastructure initiative.

UBI management believe that UBI’s Global Health Public Blockchain will be our flagship product. On this public blockchain, we not only provide services for health institutions, enterprises, hospitals, etc., but more importantly, our health public blockchain network will connect various communities. In this case, peer-to-peer non-centralized marketing will be realized, which will make marketing faster and lower in cost. Meanwhile, enterprises and consumers can establish a common value on consuming. It will also enable individuals in the community to establish their own health data leger on the public chain, so they can effectively and safely manage their own health data, and become the true manager of their own health. Health data can be used for individuals to improve their own health, and can also be managed to create economic and social benefits through data analysis and appropriate use based on consented and shared value built among community members.

~~Nova’s operations prior to the date of acquisition, included, but was not limited to:~~Manufacturing

●The Company ~~Researching~~does ~~and~~not ~~developing~~now ~~business~~engage ~~opportunities~~in ~~unique~~any tomanufacturing abut ~~Chinese~~may ~~customer~~engage ~~base~~in ●manufacturing ~~Building corporate infrastructure and administration ● Integration~~ of ~~multiple~~products ~~technologies~~to ~~and~~be ~~programs~~sold ●on ~~Building Business Relationships ● Human resource staffing ● Training personnel ● Equipment procurement ● Building~~ the ~~corporate~~ Company’s website ●in ~~Developing marketing strategies to capitalize on commercialization activities ● Establish and maintain strategic collaborations with product suppliers ● Obtain financing to implement~~ the ~~business activities~~future.

In April, 2017 Shenzhen Nova E-commerce wanted to begin its operations of an online store in China selling a wide range of products including maternal and infant products, cosmetics, wine, household goods, digital and luxury products, but was unable to begin its operations due to technical problems in processing transactions involving Chinese currency . UBI Shenzhen (formerly Nova) has yet to generate any revenues, and management does not expect UBI Shenzhen will generate any revenues for the next few months, until such time as the Company actively markets its website (www.hihealth8.com). And, there is a possibility that UBI Shenzhen will never generate any revenues.

On April 7, 2018, NOVA changed its name to UBI Shenzhen Cross Border E-Commerce Co., Ltd. (“UBI Shenzhen”). UBI Shenzhen is registered in Qianhai Free Trade Zone, China. Its business operation is its own e-commerce platform offering online retail service, via www.hihealth8.com. Its e-commerce platform is not part of our blockchain technology, but a platform to sell products on-line through the Company’s website. From its inception on May 26, 2016 through the present, UBI Shenzhen has been building its website and infrastructure. UBI Shenzhen commenced its pilot operation in May 2017.

It was a management decision to acquire UBI Shenzhen for primarily two business reasons: 1) as a separate subsidiary, once UBI Shenzhen is fully operational, management anticipates it should generate revenues and profit for the Company; and 2) this acquisition provides a test model to utilize the blockchain technology the Company is developing to track drug products sold by UBI Shenzhen. As a test model, this will allow the Company to see if the products sold through its website are substituted with counterfeit products before they reach the final consumer. In other words, products sold through a third party consumer will be tracked using the Company’s blockchain technology to see if there is a break in the supply chain. This will take place once the Company develops its blockchain digital tracking system. The Company will be able to monitor UBI Shenzhen shipments to the final consumer, to determine if there has been any tampering with shipment in the supply chain.

UBI Shenzhen’s original Chinese language website experienced a number of technical problems, especially dealing with Chinese currency. Management decided it would be more cost effective to establish a new website under the domain name. www.hihealth8.com. The website will allow people with Chinese currency who have a local Chinese bank account to purchase products through this website, where customers will be able to purchase products, including food, non-prescription medicine, skin care products etc. offered on the website. For the purpose of this Registration Statement, the website is not part of this Post-Effective Amendment, but referenced for informational purposes.

UBI Shenzhen sales will take place one of two ways. When a consumer clicks to buy product(s): (a) A third seller will sell and ship directly to the consumer and UBI Shenzhen will receive an agency fee; or (b) UBI Shenzhen will process the sale from its own inventory and ship and bill the consumer directly. These two ways methods will generate business through UBI Shenzhen. There is the possibility that the website might never generate any sales or revenue for the Company.

UBI Shenzhen employs two people principally involved in website related creation/maintenance activities. UBI Shenzhen’s expenses are being funded by loans from Tony Liu.

Recent Events

SEC Order of Trading Suspension

On January 5, 2018, the Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the “Exchange Act”), of trading in the securities of UBI Blockchain Internet, Ltd. at 9:30 a.m. EST on January 8, 2018, and terminating at 11:59 p.m. EST, on January 22, 2018. The Commission temporarily suspended trading in the securities of UBIA because of (i) questions regarding the accuracy of assertions, since at least September 2017, by UBIA in filings with the Commission regarding the company’s business operations; and (ii) concerns about recent, unusual and unexplained market activity in the company’s Class A common stock since at least November 2017.

Grey Sheets

The suspension of trading eliminated our market makers and resulted in our stock placed on the grey sheets of the OTC markets. Prior to the suspension, our stock was listed on the OTC-QB. Broker-dealers are not willing or able to publicly quote grey sheets securities because of a lack of investor interest, company information availability or regulatory compliance. Grey sheet is an unsolicited market where securities do not have bid or ask quotations. The placement on grey sheets makes our stock more difficult to trade, dramatically reduces the liquidity of our stock and has a negative impact on our investors. Further, OTC Markets has blocked quotations for our securities, and they have labeled our Class A common stock as Caveat Emptor (Buyer Beware). Broker-dealers cannot publish or submit in a quotation medium to buy or sell our stock until they have complied with Exchange Act Rule 15c2-11. In the absence of a trading market or an inactive trading market, investors may be unable to liquidate their investment or make any profit from the investment. As such, our common stock is now on the grey sheets, this adversely effects the liquidity of the shares of common stock. Investors may be unable to liquidate their investment.

Hong Kong Government Grant

On January 10, 2018, the Company announced that the Hong Kong Special Administrative Region (“HKSAR”) approved in principle a grant of up to HK 3,018,750 (approximately $385,000) to assist in financing a project entitled “Blockchain-Based Food and Drug Counterfeit Detection and Regulatory System” (“the HKPU Project”) to be jointly developed by UBI Hong Kong and The Hong Kong Polytechnic University (“HKPU”). The related agreement also provides for UBI Hong Kong to contribute up to HK $3,018,750 (approximately $385,000) to the project cost in installments with the first installment of HK$561,198 (approximately $72,000) due upon HKSAR’s signing of the agreement (which occurred on January 5, 2018). UBI Hong Kong, owned and controlled by Tony Liu, is the largest shareholder of UBI Blockchain Internet Ltd, (Delaware). Although we do not own or control UBI Hong Kong or have rights in the project or its intellectual property. UBI Hong Kong, our principal stockholder, on May 1, 2018 entered into an Assignment Agreement with UBI Delaware, whereby UBI Hong Kong assigned all of its rights, plans, ideas, tangible assets, intangible assets and intellectual property to UBI Delaware, in order for UBI Delaware to commercialize the technology being developed (See Exhibit 10.6). The project is expected to be completed by November 14, 2019. In a series of two payments made by UBI Hong Kong on January 12, 2018, and January 16, 2018, UBI Hong Kong paid its first installment of a total of HK $561,198 (approximately $71,000) to HKPU. On February 1, 2018, HKSAR paid its first installment of HK $561,198 (approximately $71,000) to HKPU. At this point, the project is progressing on track, and the parties believe the established budget will be sufficient to complete the project.

The agreement also provides for UBI Hong Kong to pay the remaining HK $2,457,552 (approximately $314,000) of its installments as follows: HK$687,934 (approximately $88,000) by April 1, 2018; HK $687,934 (approximately $88,000) by October 1, 2018; HK $687,934 (approximately $88,000) by April 1, 2019 and HK$393,750 (approximately $50,000) within three months of the completion of the HKPU Project. While UBI Hong Kong does not have the financial wherewithal to pay current installments under the agreement as due, Tony Liu has personally agreed and been able to provide funding as necessary for both operations of the Company and obligations due under the agreement. On May 11, 2018 (see Note 12), UBI Hong Kong paid HKPU a second installment of HK $643,647 (approximately $82,000). On May 24, 2018 (see Note 12), HKSAR also paid HKPU a second installment of HK $643,647 (approximately $82,000).

The agreement also provides for the HKSAR to pay the remaining HK $2,457,522 (approximately $314,000) of its installments periodically within 30 days after the acceptance by the Commissioner of Innovation and Technology (“CIT”), an agency of the HKSAR, of certain Progress Reports to be submitted periodically by HKPU. The agreement provides that HKPU should provide CIT the first written Progress Report in a format acceptable to CIT covering from the Commencement Date to August 31, 2018 to be submitted on or before September 30, 2018. While no written Progress Reports have yet been required or provided to CIT, periodic telephone conversations with CIT have occurred between CIT, HKPU, and the Company from time to time concerning HKPU Project’s progress. The agreement imposes no penalties on UBI Hong Kong should it fail to make any of its installment contributions except that HKSAR principally has the right to cease their installment contributions if UBI Hong Kong fails to make its installment contributions. HKSAR may terminate the agreement if UBI Hong Kong fails to make any of its installment contributions. Further, if any of the parties are in breach of the terms of the agreement or fail in a material way to progress in accordance with the Project Proposal, The Hong Kong Polytechnic University shall on demand by the Government pay to the Government an amount equivalent to the funds or portion thereof released for the Project.

Project Summary

The goal of this project is to provide a comprehensive solution to the worldwide problem of counterfeit medicines. Leveraging latest techniques the team want to develop a low-cost, scalable, secure system for: (1) Manufacturers to record necessary data of the drugs during their production and transportation; (2) Distributors to trace the drugs; (3) Auditors to inspect all data; and finally (4) Consumers to verify the authenticity of the purchased product. This platform will provide suppliers of food and drug products a safety control system to determine if there was a break in the supply chain. It will identify if a product was substituted with a counterfeit or inferior product. It will help suppliers of perishable food products, reduce spoilage by tracking food shipments in the supply chain to the final consumer. The safety control system is be designed to prevent unforeseen conditions from occurring. It will be integrated into our technology to help us determine if there has been a break in our tracking systems. It is being developed with HKPU and is required for the completion of this project.

In February 2018, UBI Hong Kong performed a test at the offices of Guangxi Houde Mega Health Enterprise (“Guangxi”), a medical products company, of the e-commerce “alpha” platform (using simulated test data provided by Guangxi). Guangxi is owned 70% by Star Bright International Enterprise Ltd. Star Bright is a stockholder offering 5,000,000 resale Class C common shares in this registration statement. The test identified some technical issues that need to be addressed; the team is currently preparing for a second test. The second test, originally scheduled for June 2018, will not be scheduled until the team believes the test will be successful. The e-commerce platform will provide a digital shared accounting ledger that would make it possible to trace back a product to the very origin of the raw material used.

Once a working model of a platform is successfully operational, the Company intends to license the software to larger food and drug third party customers.

The agreement provides that the equipment acquired from the HKPU Project will belong to HKPU, who is also identified as the Beneficiary of the grant for the project and is required to provide CIT with interim and a final accounting for the proceeds of the grant as well as monies advanced by UBI Hong Kong whether the project is successful or not. While HKPU, as the Beneficiary, is provided discretion on how income arising from the intellectual property rights from the Project Materials (including among other things computer software/programs, technical materials, models, documents and materials compiled developed, produced or created by or on behalf of the Beneficiary – the “platform.” and Project Result is to be allocated, UBI Hong Kong is the sole and absolute beneficial owner (has title to) of all of the intellectual property rights which would include the platform if successfully completed under the project.

While HKPU receives full legal and equitable title and interest in any and all of the equipment procured by the Beneficiary, the agreement does not discuss whether HKPU can discontinue its own performance in the event the either HKSAR or UBI Hong Kong fail to make the required payments. However, without funding no one would expect that HKPU would be obligated to continue its performance.

The Company expects to use the technology learned from the HKPU Project to help it develop and market a platform system for application to control and manage the safety of food and drugs. Pursuant to an understanding with UBI Hong Kong, the Company is responsible for the installments due and other costs relating to the HKPU Project paid by UBI Hong Kong. These costs are expected to be paid by UBI Hong Kong from loans received from the Company’s CEO Tony Liu. The Company expects to record these costs as research and development expenses and increases in amounts due to Tony Liu until such time as a “technologically feasible” working model of the platform has been successfully produced.

Government Regulation

We are or may become subject to a variety of laws and regulations in the State of Delaware, where we are incorporated, the United States and the People’s Republic of China (“PRC”) that involve matters central to our business, including laws and regulations regarding privacy, data protection, data security, data retention, consumer protection, advertising, electronic commerce, intellectual property, manufacturing, anti-bribery and anti-corruption, and economic or other trade prohibitions or sanctions. These laws and regulations are continuously evolving and developing. The scope and interpretation of the laws that are or may be applicable to us are often uncertain and may be conflicting, particularly with respect to foreign laws.

In particular, there are numerous U.S. federal, state, and local laws and regulations and foreign laws and regulations regarding privacy and the collection, sharing, use, processing, disclosure, and protection of personal information and other user data, the scope of which is changing, subject to differing interpretations, and may be inconsistent among different jurisdictions. We strive to comply with all applicable laws, policies, legal obligations, and industry codes of conduct relating to privacy, data security, and data protection. However, given that the scope, interpretation, and application of these laws and regulations are often uncertain and may be conflicting, it is possible that these obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules or our practices. Any failure or perceived failure to comply with our privacy or security policies or privacy-related legal obligations by us or third-party service-providers or the failure or perceived failure by third-party apps, with which our users choose to share their data, to comply with their privacy policies or privacy-related legal obligations as they relate to the data shared with them, or any compromise of security that results in the unauthorized release or transfer of personally identifiable information or other user data, may result in governmental enforcement actions, litigation, or negative publicity, and could have an adverse effect on our brand and operating results.

We plan to develop solutions to ensure that data transfers from the E.U. provide adequate protections to comply with the E.U. Data Protection Directive. If we fail to develop such alternative data transfer solutions, one or more national data protection authorities in the European Union could bring enforcement actions seeking to prohibit or suspend our data transfers to the U.S. and we could also face additional legal liability, fines, negative publicity, and resulting loss of business.

Governments are continuing to focus on privacy and data security and it is possible that new privacy or data security laws will be passed or existing laws will be amended in a way that is material to our business. Any significant change to applicable laws, regulations, or industry practices regarding our users’ data could require us to modify our services and features, possibly in a material manner, and may limit our ability to develop new products, services, and features. Although we have made efforts to design our policies, procedures, and systems to comply with the current requirements of applicable state, federal, and foreign laws, changes to applicable laws and regulations in this area could subject us to additional regulation and oversight, any of which could significantly increase our operating costs.

The labeling, distribution, importation, marketing, and sale of our intended products are subject to extensive regulation by various U.S. state and federal and foreign agencies, including the CPSC, Federal Trade Commission, Food and Drug Administration, or FDA, Federal Communications Commission, and state attorneys general, as well as by various other federal, state, provincial, local, and international regulatory authorities in the countries in which our intended products and services are distributed or sold. If we fail to comply with any of these regulations, we could become subject to enforcement actions or the imposition of significant monetary fines, other penalties, or claims, which could harm our operating results or our ability to conduct our business.

The global nature of our business operations also create various domestic and foreign regulatory challenges and subject us to laws and regulations such as the U.S. Foreign Corrupt Practices Act, or FCPA, the U.K. Bribery Act, and similar anti-bribery and anti-corruption laws in other jurisdictions, and our intended products are also subject to U.S. export controls, including the U.S. Department of Commerce’s Export Administration Regulations and various economic and trade sanctions regulations established by the Treasury Department’s Office of Foreign Assets Controls. If we become liable under these laws or regulations, we may be forced to implement new measures to reduce our exposure to this liability. This may require us to expend substantial resources or to discontinue certain products or services, which would negatively affect our business, financial condition, and operating results. In addition, the increased attention focused upon liability issues as a result of lawsuits, regulatory proceedings, and legislative proposals could harm our brand or otherwise impact the growth of our business. Any costs incurred as a result of compliance or other liabilities under these laws or regulations could harm our business and operating results.

PRC Government Regulations

Because our business and employees are located in the PRC, our business is also regulated by the national and local laws of the PRC. We believe our conduct of business complies with existing PRC laws, rules and regulations.

General Regulation of Businesses

We believe we are in material compliance with all applicable labor and safety laws and regulations in the PRC, including the PRC Labor Contract Law, the PRC Production Safety Law, the PRC Regulation for Insurance for Labor Injury, the PRC Unemployment Insurance Law, the PRC Provisional Insurance Measures for Maternity of Employees, PRC Interim Provisions on Registration of Social Insurance, PRC Interim Regulation on the Collection and Payment of Social Insurance Premiums and other related regulations, rules and provisions issued by the relevant governmental authorities from time to time.

According to the PRC Labor Contract Law, we are required to enter into labor contracts with our employees. We are required to pay no less than local minimum wages to our employees. We are also required to provide employees with labor safety and sanitation conditions meeting PRC government laws and regulations and carry out regular health examinations of our employees engaged in hazardous occupations. Violations of the PRC Labor Contract Law and the PRC Labor Law may result in the imposition of fines and other administrative and criminal liability in the case of serious violations. In addition, according to the PRC Social Insurance Law, employers like our PRC subsidiaries in China must provide employees with welfare schemes covering pension insurance, unemployment insurance, maternity insurance, work-related injury insurance, medical insurance, and housing funds.

29Foreign Currency Exchange

The principal regulation governing foreign currency exchange in China is the Foreign Currency Administration Rules (1996), as amended (2008). Under these Rules, RMB is freely convertible for current account items, such as trade and service-related foreign exchange transactions, but not for capital account items, such as direct investment, loan or investment in securities outside China unless the prior approval of, and/or registration with, the State Administration of Foreign Exchange of the People’s Republic of China, or SAFE, or its local counterparts (as the case may be) is obtained.

Pursuant to the Foreign Currency Administration Rules, foreign invested enterprises, or FIEs, in China may purchase foreign currency without the approval of SAFE for trade and service-related foreign exchange transactions by providing commercial documents evidencing these transactions. They may also retain foreign exchange (subject to a cap approved by SAFE) to satisfy foreign exchange liabilities or to pay dividends. In addition, if a foreign company acquires a subsidiary in China, the acquired company will also become an FIE. However, the relevant PRC government authorities may limit or eliminate the ability of FIEs to purchase and retain foreign currencies in the future. In addition, foreign exchange transactions for direct investment, loan and investment in securities outside China are still subject to limitations and require approvals from, and/or registration with, SAFE.

Employees

We have 18 full-time employees and we engage the services of47 44 non-employee contractors. Within our workforce, 8 employees are engaged in product and business development and 10 employees are engaged in ~~business development,~~ finance, human resources, facilities, information technology and general management and administration. We ~~expect the number of full time employees to rise to more than 25 by the end of September, 2018. We~~ have no collective bargaining agreements with our employees and we have not experienced any work stoppages. We consider our relationship with our employees to be good.

Property

The Company owns no real property. Our administrative offices are located at: SmartSpace 3F, Level 9, Unit 908, 100 Cyberport Rd., Hong Kong, People’s Republic of China., telephone: (212) 372-8836. The Company has been using this Hong Kong office space provided by UBI ~~Blockchain Internet, LTD. (a~~ Hong Kong ~~Company) (“UBI Hong Kong”)~~ at a cost to the Company equal to UBI Hong Kong’s monthly rent of 22,100 Hong Kong Dollars (approximately $2,~~816~~825 at the ~~May~~November 3130, 2018 exchange rate). UBI Hong Kong owns 30,000,000 shares of the Company’s Class A common stock, 6,000,000 shares of the Company’s Class B common stock; and 40,000,000 shares of the Company’s C common stock.

Results of Operations

Three Months Ended ~~May~~November 3130, 2018 Compared to Three Months Ended ~~May~~November 3130, 2017

Revenues

During the three-month period ended ~~May~~November 3130, 2018, ~~and~~the ~~2017~~Company recognized $112,445 revenue from development agreements and the Company had no revenues in 2017.

Expenses

For the three months ended ~~May~~November 3130, 2018, the Company had total operating expenses of $~~574~~553,~~931~~923 as compared to $~~668~~1,~~669~~223,524 for the same period in 2017, a decrease of $93669,~~738~~601, or 1455% ~~in 2017~~. For the three months ended ~~May~~November 3130, 2018, operating expenses consisted of employee compensation of $~~180~~173,~~980~~552 (including stock-based compensation of $0), consulting fees of $185,000 (stock-based compensation of $185,000), ~~depreciation and amortization of $6,697,~~ professional fees of $6168,~~280~~620, ~~rent~~occupancy expense of $2532,~~359~~653, ~~research~~ and ~~development expenditure of $86,717 and~~ other operating expenses of $2894,~~898~~098. For the three months ended ~~May 31~~November 30, 2017, the Company’s operating expenses consisted of: of employee compensation of $~~190~~263,~~701~~963 (including stock-based compensation of $72,500), consulting fees of $~~409~~532,~~167~~500, which was stock-based compensation, ~~depreciation~~professional ~~and~~fee ~~amortization~~ of $~~318~~343,872 (stock-based ~~professional~~compensation ~~fees~~of $335,872), occupancy expense of $5316,~~652~~621 and other operating expenses of $1466,~~831~~568. The decrease in operating expenses resulted from the ~~$296,667~~decreases ~~decrease~~ in ~~stock-based~~employee compensation ~~from $481~~,~~667~~ inconsulting ~~2017 to $185~~fees,~~000~~ inand ~~2018,~~professional ~~offset~~fees bydue ~~the $202,929 increase in non stock-based operating expenses from $187,002 in 2017~~ to ~~$389,931 in 2018. The increase in non~~lower stock-based ~~operating expenses was due primarily to (1) $101~~compensation,~~770~~ ~~UBI~~offset ~~Shenzhen~~by ~~operating~~the ~~expenses~~increases ~~incurred~~ in ~~the~~occupancy ~~three~~expense ~~months ended May 31, 2018,~~ and ~~(2)~~other ~~the~~operating ~~incurrence of $82,035 of research and development~~ expenses ~~in 2018 relating to the Hong Kong Polytechnic University Project which started in January 2018~~.

OnFor ~~May~~the 11three months ended November 30, 2018, ~~UBI~~the ~~Hong~~interest ~~Kong~~expense ~~paid~~accrued ~~HKPU~~for aloan ~~second~~from ~~installment~~Tony ofLiu HKwas $~~643~~34,~~647 (approximately $82~~781,~~000)~~ ~~for~~an ~~the~~increase ~~HKPU project. The first payment~~ of HK$ ~~561~~23,~~198 (approximately $71~~955,~~779) was made on January 16, 2018. The Company charged these payments as research and~~ ~~development~~compared ~~expenses. The Company will continue~~ to ~~charge~~$10,826 ~~future~~in ~~HKPU project payments as R&D expense until such time as a “technologically feasible” working model of~~ the ~~platform~~three ~~has~~months ~~been~~ended ~~successfully~~November ~~produced~~30, 2017.

For the three months ended May 31, 2018, the interest expense accrued for loans from Tony Liu was $24,024. For the three months ended May 31, 2017, there was no interest accrued for loans from Tony Liu.

Net Loss

For the three months ended ~~May~~November 3130, 2018, the Company had a net loss of $~~599~~476,~~112~~458 or $(0.0100) per share of Class A, ~~Class B,~~ and Class C common stock and compared to a loss of $~~668~~1,~~669~~234,340 or $(0.01) per share of Class A, ~~Class B,~~ and Class C common stock for the same period last year.

Nine Months Ended May 31, 2018 Compared to Nine Months Ended May 31, 2017

Revenues

During the nine-month period ended May 31, 2018 and 2017, the Company had no revenues.

Expenses

For the nine months ended May 31, 2018, the Company had total operating expenses of $2,453,529 as compared to $1,170,660 in 2017. For the nine months ended May 31, 2018, operating expenses consisted of employee compensation of $641,036 (including stock-based compensation of $96,668), consulting fees of $1,023,383 (stock-based compensation of $1,018,333), depreciation and amortization of $11,021, professional fees of $454,152 (stock-based compensation of $335,872), rent expense of $65,049, research and development expenditure of $158,496 and other operating expenses of $100,392. For the nine months ended May 31, 2017, the Company’s operating expenses consisted of: employee compensation of $370,270 (including stock-based compensation of $120,833), consulting fees of $665,834 (stock-based compensation of $640,834), depreciation and amortization of $318, professional fees of $93,168 and other operating expenses of $41,070. The $1,282,869 increase in operating expenses resulted from the $689,206 increase in stock-based compensation from $761,667 in 2017 to $1,450,873 in 2018 and the $593,663 increase in non stock-based operating expenses from $408,993 in 2017 to $1,002,656 in 2018. The increase in non stock-based operating expenses was due primarily to (1) $268,427 UBI Shenzhen operating expenses incurred in the nine months ended May 31,2018, (2) the incurrence of $153,814 of research and development expenses in 2018 relating to the Hong Kong Polytechnic University Project which started in January 2018 and, (3) the $157,315 increase in UBI Hong Kong employee compensation in 2018.

On May 11, 2018, UBI Hong Kong paid HKPU a second installment of HK $643,647 ($82,035) for the HKPU project. The first payment of HK$ 561,198 ($71,779) was made on January 16, 2018. The Company charged these payments as research and development expenses. The Company will continue to charge future HKPU project payments as R&D expense until such time as a “technologically feasible” working model of the platform has been successfully produced

For the nine months ended May 31, 2018, the interest expense accrued for loans from Tony Liu was $52,869.

For the nine months ended May 31, 2017, the Company had a gain of $47,003 from settlement of accounts payable and accrued liabilities and a gain of $572 from settlement of a bank overdraft.

Net Loss

For the nine months ended May 31, 2018, the Company had a net loss of $2,506,613 or $(0.02) per share of Class A, Class B, and Class C common stock and compared to a loss of $1,123,085 or $(0.03) per share of Class A, Class B, and Class C common stock for the same period last year.

Going Concern

At ~~May~~November 3130, 2018, the Company had cash of $55189,~~245~~323 and current liabilities of $12,~~732~~525,~~425~~753. For the ~~nine~~three months ended ~~May 31~~November 30, 2018, the Company incurred a net loss of $2476,~~506,613~~458. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company’s ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and its ability to achieve and maintain profitable operations. Management plans to raise equity capital to finance the operating and capital requirements of the Company. Amounts raised will be used to further development of the Company’s services, to provide financing for marketing and promotion and for other working capital purposes. While the Company is putting forth its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds that will be available for operations.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Our financial statements do not include any adjustments that might arise from this uncertainty.

Liquidity and Capital Resources

As of ~~May~~November 3130, 2018, the Company ~~had~~has total assets of $~~893~~671,~~818~~113 consisting of cash $55189,~~245~~323, inventory of $2523,~~025~~083, prepaid stock-based compensation of $~~678~~308,333, deposit and prepaid ~~expenses~~expense of $~~3.691~~25,651, office equipment of $207,~~729~~170 and ~~intangible~~capitalized ~~assets~~website development costs of $~~110~~117,~~795~~553. ~~and~~Total ~~total~~ liabilities ofis $12,~~732~~525,~~425~~753 as of November 30, 2018.

The Company ~~has~~started ~~not~~to ~~generated~~generate ~~any~~limited income asfrom ofproject ~~May~~development 31during the quarter ended November 30, 2018. The working capital was provided by a major shareholder of the Company. The Company has limited financial resources available, which has had an adverse impact on the Company’s liquidity, activities and operations. These limitations have adversely affected the Company’s ability to obtain certain projects and pursue additional business. Without realization of additional capital, it would be unlikely for the Company to continue as a going concern. In order for the Company to remain a Going Concern it will need to find additional capital. Additional working capital may be sought through additional debt or equity private placements, additional notes payable to banks or related parties (officers, directors or stockholders), or from other available funding sources at market rates of interest, or a combination of these. The ability to raise necessary financing will depend on many factors, including the nature and prospects of any business to be acquired and the economic and market conditions prevailing at the time financing is sought. No assurances can be given that any necessary financing can be obtained on terms favorable to the Company, or at all.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies and Estimates

Revenue Recognition: We recognize revenue from services and product sales once all of the following criteria for revenue recognition have been met: pervasive evidence that an agreement exists; the services have been rendered; or the ~~products have been delivered; the~~ fee is fixed and determinable and not subject to refund or adjustment; and collection of the amount due is reasonable assured.

New Accounting Standards

Management has evaluated recently issued accounting pronouncements through ~~May~~November 3130, 2018 and concluded that they will not have a material effect on future financial statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not required for smaller reporting companies.

33Item 4. Controls and Procedures

Item 4T. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in rules and forms adopted by the SEC, and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

Management, with the participation of the Chief Executive Officer and the Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the quarterly period covered by this report. Based on such evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that, our disclosure controls and procedures were ~~not~~ effective. Our disclosure controls and procedures were not effective because of the “material weaknesses” described below under “Management’s report on internal control over financial reporting,” which are in the process of being remediated as described below under “Management Plan to Remediate Material Weaknesses.”

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting, as defined in rules promulgated under the Exchange Act, is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and affected by our Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Internal control over financial reporting includes those policies and procedures that:

● pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; ● provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our Board of Directors; and ● provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable, not absolute, assurance that the objectives of the control system are met and may not prevent or detect misstatements. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process, and it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Further, over time control may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of May 31, 2018. In making its assessment, management used the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on its assessment, management has concluded that we had certain control deficiencies described below that constituted material weaknesses in our internal controls over financial reporting. As a result, our internal control over financial reporting was not effective as of May 31, 2018.

A “material weakness” is defined under SEC rules as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls. As a result of management’s review of the investigation issues and results, and other internal reviews and evaluations that were completed after the end of quarter related to the preparation of management’s report on internal controls over financial reporting required for this quarterly report on Form 10-Q, management concluded that we had material weaknesses in our control environment and financial reporting process consisting of the following:

	1)	lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; and
	2)	insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements.

We do not believe the material weaknesses described above caused any meaningful or significant misreporting of our financial condition and results of operations for the quarter ended May 31, 2018. However, management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Management Plan to Remediate Material Weaknesses

Management is pursuing the implementation of corrective measures to address the material weaknesses described below. In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, the following series of measures:

We will create a position to segregate duties consistent with control objectives and will increase our personnel resources and technical accounting expertise within the accounting function when funds are available to us. We plan to appoint one or more outside directors to our board of directors who shall be appointed to an audit committee resulting in a fully functioning audit committee who will undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and approving estimates and assumptions made by management when funds are available to us.

We believe the remediation measures described above will remediate the material weaknesses we have identified and strengthen our internal control over financial reporting. We are committed to continuing to improve our internal control processes and will continue to diligently and vigorously review our financial reporting controls and procedures. As we continue to evaluate and work to improve our internal control over financial reporting, we may determine to take additional measures to address control deficiencies or determine to modify, or in appropriate circumstances not to complete, certain of the remediation measures described above.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the ~~most~~quarterly ~~recent~~period ~~fiscal~~covered ~~quarter~~by this report that have materially affected, or are reasonably likely to ~~materially~~ materially affect, our internal control over financial reporting.

3627

PART II. OTHER INFORMATION

Item 1 — Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

We are not presently a party to any material litigation, nor to the knowledge of management is any litigation threatened against us, which may materially affect us.

Item 1A - — Risk Factors

See Risk Factors set forth in Part I, Item 1A of the Company’s Annual Report on 10-K for the fiscal year ended August 31, ~~2017~~2018 and the discussion in Item 2 of Part I above, under “Liquidity and Capital Resources.” Additionally see Risk Factors set forth in the Form 10 Information disclosed in the Company’s Amended Current Report in Form 8-K/A filed in the Commission on November 17, 2017 and the Post Effective Amendment No. 5 to Form S-1 Filed with the Commission on July 2, 2018.

Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3 — Defaults Upon Senior Securities

None.

Item 4 — ~~Submission~~Mine ofSafety ~~Matters to a Vote of Security Holders~~Disclosures

None.

Item 5 — Other Information

The Company filed a Registration Statement on Form S-1, that registered 20,582,000 of our Class A Common Stock, par value $0.001, and 51,700,000 shares of our Class C Common Stock, par value $0.001. The Registration became effective on December 22, 2017. After the stock suspension Notice was issued, the Commission asked the Company to file a Post-Effective Amendment to disclose the stock suspension and its ramifications. The Company filed a Post-Effective Amendment No. 1 on February 5, 2018, Post-Effective Amendment No. 2 on April 4, 2018, Post-Effective Amendment No. 3 on April 19, 2018, Post-Effective Amendment No. 4 on May 15, 2018, and Post-Effective Amendment No. 5 on July 2, 2018.

Item 6 — Exhibits

Exhibit Number	~~Ref~~	Description of Document
31.1		Certifications of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certifications of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
101	*	The following materials from this Quarterly Report on Form 10-Q for the quarter ended May 31, 2018, formatted in XBRL (eXtensible Business Reporting Language):
		(1) Balance Sheets at May 31, 2018 (Unaudited) and August 31, 2017 (Audited).
		(1) Balance Sheets at November 30, 2018 (Unaudited) and August 31, 2017 (Audited).
		(2) Unaudited Statements of Operations for the three and nine-month periods ended May 31, 2018 and 2017.
		(2) Unaudited Statements of Operations for the three month periods ended November 30, 2018 and 2017.
		(3) Unaudited Statements of Cash Flows for the nine month periods ended May 31, 2018 and 2017.
		(3) Unaudited Statements of Cash Flows for the three month periods ended November 30, 2018 and 2017.
		(4) Notes to the financial statements (Unaudited).

3828

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	UBI Blockchain Internet, Ltd. Registrant
Date: July 15, 2018	By:	/s/ Tony Liu
Date: January 16, 2019	By:	/s/ Tony Liu
	Name:	Tony Liu
		Principal Executive Officer
Date: July 15, 2018	By:	/s/ Chan Cheung
Date: January 16, 2019	By:	/s/ Chan Cheung
	Name:	Chan Cheung
		Principal Accounting Officer

3929

Filing Compare · UBI Blockchain Internet LTD-DE